<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22C15C82-7C78-474C-A946-E96D7705AFFF"><gtr:id>22C15C82-7C78-474C-A946-E96D7705AFFF</gtr:id><gtr:name>Scandinavian Sarcoma Group (SSG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50D230BC-805B-45A1-81B6-BA53637AC613"><gtr:id>50D230BC-805B-45A1-81B6-BA53637AC613</gtr:id><gtr:name>Irish Clinical Oncology Research Group (ICORG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5170A240-CBC7-44C6-ABED-00FDE7F3FB97"><gtr:id>5170A240-CBC7-44C6-ABED-00FDE7F3FB97</gtr:id><gtr:name>Wales Cancer Bank</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/05301658-E204-428F-A5F5-3BA794DECB49"><gtr:id>05301658-E204-428F-A5F5-3BA794DECB49</gtr:id><gtr:name>Danish Cancer Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9A70B68-57E0-4980-8B78-35EC3EF12BB1"><gtr:id>B9A70B68-57E0-4980-8B78-35EC3EF12BB1</gtr:id><gtr:name>Cooperative Osteosarcoma Study Group (COSS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFD03F41-1644-48B5-A968-B21367E36432"><gtr:id>AFD03F41-1644-48B5-A968-B21367E36432</gtr:id><gtr:name>Gynecologic Cancer InterGroup (GCIG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ED28E77E-59C1-4572-8D58-6FDC7D27006E"><gtr:id>ED28E77E-59C1-4572-8D58-6FDC7D27006E</gtr:id><gtr:name>Clovis Oncology, inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A854D267-576A-4F36-8368-96E7D93011C3"><gtr:id>A854D267-576A-4F36-8368-96E7D93011C3</gtr:id><gtr:name>Australia and New Zealand Gynaecological Oncology Group (ANZGOG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8E8A3FEA-5D67-4375-90D7-AE76E2C9F828"><gtr:id>8E8A3FEA-5D67-4375-90D7-AE76E2C9F828</gtr:id><gtr:name>European Society of Gynaecological Oncology (ESGO)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A901D7C4-01EF-4E4A-9974-2F5DF988FF22"><gtr:id>A901D7C4-01EF-4E4A-9974-2F5DF988FF22</gtr:id><gtr:name>Research Group on Ovarian Cancer and Gynecologic Tumors of Mexico (GICOM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C"><gtr:id>EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C</gtr:id><gtr:name>St Bartholomew's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/308580CA-D87F-457B-BD9F-4180BEAA898E"><gtr:id>308580CA-D87F-457B-BD9F-4180BEAA898E</gtr:id><gtr:name>Alcura</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE2E287C-1032-4E67-A818-BDD930F15778"><gtr:id>FE2E287C-1032-4E67-A818-BDD930F15778</gtr:id><gtr:name>Canadian Cancer Trials Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B589281B-BE51-4D64-96A8-B62BDE6E23AB"><gtr:id>B589281B-BE51-4D64-96A8-B62BDE6E23AB</gtr:id><gtr:name>Canadian Cancer Society Research Institute (CCSRI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B7BD8763-9E4F-43AB-B9F4-6FCB9F78A921"><gtr:id>B7BD8763-9E4F-43AB-B9F4-6FCB9F78A921</gtr:id><gtr:name>Korean Gynaecological Oncology Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/895FC161-2794-46E4-9899-347044E3B076"><gtr:id>895FC161-2794-46E4-9899-347044E3B076</gtr:id><gtr:name>National Cancer Institute of Canada Clinical Trials Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/988EC845-6400-42E1-A3C0-43B5601C2BB6"><gtr:id>988EC845-6400-42E1-A3C0-43B5601C2BB6</gtr:id><gtr:name>Sir Dorabji Tata Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6"><gtr:id>E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6</gtr:id><gtr:name>European and American Osteosarcoma Study Group (EURAMOS)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22C15C82-7C78-474C-A946-E96D7705AFFF"><gtr:id>22C15C82-7C78-474C-A946-E96D7705AFFF</gtr:id><gtr:name>Scandinavian Sarcoma Group (SSG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50D230BC-805B-45A1-81B6-BA53637AC613"><gtr:id>50D230BC-805B-45A1-81B6-BA53637AC613</gtr:id><gtr:name>Irish Clinical Oncology Research Group (ICORG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5170A240-CBC7-44C6-ABED-00FDE7F3FB97"><gtr:id>5170A240-CBC7-44C6-ABED-00FDE7F3FB97</gtr:id><gtr:name>Wales Cancer Bank</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/05301658-E204-428F-A5F5-3BA794DECB49"><gtr:id>05301658-E204-428F-A5F5-3BA794DECB49</gtr:id><gtr:name>Danish Cancer Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9A70B68-57E0-4980-8B78-35EC3EF12BB1"><gtr:id>B9A70B68-57E0-4980-8B78-35EC3EF12BB1</gtr:id><gtr:name>Cooperative Osteosarcoma Study Group (COSS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFD03F41-1644-48B5-A968-B21367E36432"><gtr:id>AFD03F41-1644-48B5-A968-B21367E36432</gtr:id><gtr:name>Gynecologic Cancer InterGroup (GCIG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED28E77E-59C1-4572-8D58-6FDC7D27006E"><gtr:id>ED28E77E-59C1-4572-8D58-6FDC7D27006E</gtr:id><gtr:name>Clovis Oncology, inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A854D267-576A-4F36-8368-96E7D93011C3"><gtr:id>A854D267-576A-4F36-8368-96E7D93011C3</gtr:id><gtr:name>Australia and New Zealand Gynaecological Oncology Group (ANZGOG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E8A3FEA-5D67-4375-90D7-AE76E2C9F828"><gtr:id>8E8A3FEA-5D67-4375-90D7-AE76E2C9F828</gtr:id><gtr:name>European Society of Gynaecological Oncology (ESGO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A901D7C4-01EF-4E4A-9974-2F5DF988FF22"><gtr:id>A901D7C4-01EF-4E4A-9974-2F5DF988FF22</gtr:id><gtr:name>Research Group on Ovarian Cancer and Gynecologic Tumors of Mexico (GICOM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C"><gtr:id>EC3E824E-993A-4DE4-89E3-F3DCA7ACC32C</gtr:id><gtr:name>St Bartholomew's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/308580CA-D87F-457B-BD9F-4180BEAA898E"><gtr:id>308580CA-D87F-457B-BD9F-4180BEAA898E</gtr:id><gtr:name>Alcura</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE2E287C-1032-4E67-A818-BDD930F15778"><gtr:id>FE2E287C-1032-4E67-A818-BDD930F15778</gtr:id><gtr:name>Canadian Cancer Trials Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B589281B-BE51-4D64-96A8-B62BDE6E23AB"><gtr:id>B589281B-BE51-4D64-96A8-B62BDE6E23AB</gtr:id><gtr:name>Canadian Cancer Society Research Institute (CCSRI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B7BD8763-9E4F-43AB-B9F4-6FCB9F78A921"><gtr:id>B7BD8763-9E4F-43AB-B9F4-6FCB9F78A921</gtr:id><gtr:name>Korean Gynaecological Oncology Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/895FC161-2794-46E4-9899-347044E3B076"><gtr:id>895FC161-2794-46E4-9899-347044E3B076</gtr:id><gtr:name>National Cancer Institute of Canada Clinical Trials Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/988EC845-6400-42E1-A3C0-43B5601C2BB6"><gtr:id>988EC845-6400-42E1-A3C0-43B5601C2BB6</gtr:id><gtr:name>Sir Dorabji Tata Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6"><gtr:id>E00B55DD-8384-4AFE-8BD6-B5A47DD6CBC6</gtr:id><gtr:name>European and American Osteosarcoma Study Group (EURAMOS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3591B22B-5D64-4E64-88AB-6FF834EBF6BF"><gtr:id>3591B22B-5D64-4E64-88AB-6FF834EBF6BF</gtr:id><gtr:firstName>Ruth</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Langley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9"><gtr:id>A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Sydes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0A1A9F6-1AA6-4F4E-8CB7-B1274A99660F"><gtr:id>A0A1A9F6-1AA6-4F4E-8CB7-B1274A99660F</gtr:id><gtr:firstName>Louise</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>BROWN</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0C59F358-7424-439C-BECF-3CF953EA65F3"><gtr:id>0C59F358-7424-439C-BECF-3CF953EA65F3</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Kaplan</gtr:surname><gtr:orcidId>0000-0002-0189-8348</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5F4BE39D-6ED2-4946-AEB1-C681240D3A57"><gtr:id>5F4BE39D-6ED2-4946-AEB1-C681240D3A57</gtr:id><gtr:firstName>Jayne</gtr:firstName><gtr:surname>Tierney</gtr:surname><gtr:orcidId>0000-0002-4734-3014</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C2ADAD1C-4A0B-4FFE-BEC7-6C6CAF45BB60"><gtr:id>C2ADAD1C-4A0B-4FFE-BEC7-6C6CAF45BB60</gtr:id><gtr:firstName>Max</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F28"><gtr:id>1BCAF1CB-1489-449B-9E2A-2AD84EE6D661</gtr:id><gtr:title>CANCER: Trials with potential global reach and other challenging trials</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/28</gtr:grantReference><gtr:abstractText>This program includes clinical trials that either present unusual challenges to design and conduct and/or have the potential for global impact (that is, studies of treatments that may more easily applied in even resource-poor countries).
Some of these trials test ?repurposing? an approved and marketed drug in an indication distinct from that for which it was licensed, thereby shortening the time needed to make a drug available to patients, and at lower cost.
Another area of focus has to do with the handful of cancer types in which there is a clear association to particular types of infections, such as hepatitis, helicobacter pylori, and human papilloma virus (HPV).
Finally, we use systematic reviews (compiling data from trials already completed anywhere) to identify areas of potential high-impact for new trials, for instance in relation to accuracy of prostate cancer diagnosis.</gtr:abstractText><gtr:technicalSummary>This theme relates to trials that either present unusual challenges to design and conduct and/or have the potential for global impact (that is, studies of specific relevance to both resource-poor and resource-rich countries). Challenging trials include those that draw upon this Unit?s specialised experience, such as those requiring extremely large recruitment numbers and/or practical experience managing international collaboration.
One class of trials with global reach involves tests of ?repurposing? an approved and marketed drug in an indication distinct from that for which it was licensed. There is currently considerable interest in re-evaluating commonly prescribed medications for their anti-cancer properties. 
Repurposing studies have significant potential benefits. Demonstrating efficacy in a new clinical indication for drugs with known toxicity and pharmacokinetics bypasses or shortens some of the steps of the traditional drug evaluation pathway. It also provides access to drugs that are often relatively simple to administer and considerably less expensive than newer agents still within their patent life, and therefore of particular benefit in resource-limited settings. The assessment of aspirin as an adjuvant therapy in several different cancer types within the Add-Aspirin programme is a classic example of such repurposing, as is the ongoing PATCH trial which is evaluating oestradiol patches, designed originally for use in post-menopausal women, as a treatment for prostate cancer. 
Systematic review is a key tool for deciding which agents are the best candidates for further evaluation; statins, vitamin D and metformin (an oral hypoglycaemic agent used to treat diabetes), amongst others, are currently being actively investigated for inclusion in either the STAMPEDE and/or the Add-Aspirin trial platforms.
In low resource countries, approximately one quarter of all cancers have been attributed to four chronic infectious causes: helicobacter pylori, hepatitis B and C, and human papilloma virus (HPV). HPV-associated tumours develop mainly in the ano-genital area and oropharynx and all have similar molecular signatures and clinical characteristics. We are actively exploring the feasibility of new platform trials that will bring together researchers with a common interest in HPV-related (or other infection-related) cancers. HPV cancers all contain foreign HPV antigens, which provides an opportunity to exploit immunological based therapies and strategies that have recently led to improved outcomes in other tumour types.
Some cancer trials fit into our portfolio because of particular challenges and their potential impact. Amongst these is the PROMIS study which is testing, in patients with suspected prostate cancer, a diagnostic pathway that includes Multi-Parametric Magnetic Resonance Imaging (MP-MRI). Whilst this is a UK-only study, it is in an extremely common disease setting and has the potential to reduce the substantial over-diagnosis and overtreatment of low grade prostate cancers that carry little risk to survival ? a common problem across Western countries. Improving the diagnostic accuracy for prostate cancer, the most common neoplasm in men, would have a huge impact on resource usage, outcomes, and quality of life. Perhaps most importantly, it could provide the basis for a sound approach to prostate cancer screening which has thus far proved a challenge to public health authorities internationally.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1590000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Tayside Biorepository</gtr:department><gtr:description>Add-Aspirin - Tayside tissue Bank</gtr:description><gtr:id>F5DC558A-86CD-4A31-BC96-152075AC8DAB</gtr:id><gtr:impact>The trial sample collection was initiated at the time that the trial opened to recruitment (October 2015) - collection of samples is currently ongoing. Translational work utilising the samples is being planned.</gtr:impact><gtr:outcomeId>56db6ff7d65e71.86003508-1</gtr:outcomeId><gtr:partnerContribution>Tayside Tissue Bank will host the Add-Aspirin sample collection in the UK (jointly with Wales Cancer Bank) - receiving, processing and storing samples from participating trial sites.</gtr:partnerContribution><gtr:piContribution>We are leading and co-ordinating the Add-Aspirin clinical trial and the associated collection of biological samples from trial participants.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brighton and Sussex University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Vitamin D as a cancer therapy</gtr:description><gtr:id>62FB2011-5CA9-4349-B7B0-ACC9ED8B942F</gtr:id><gtr:impact>One manuscript published (PMID: 26520788)</gtr:impact><gtr:outcomeId>56d6d58f336ec7.80197354-1</gtr:outcomeId><gtr:partnerContribution>Collated information and wrote the majority of the manuscript</gtr:partnerContribution><gtr:piContribution>Assisted in searching for trials, categorised trials, tabulated results, contributed to manuscript and interpretation of results</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gynecologic Cancer InterGroup (GCIG)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Gynecologic Cancer InterGroup (GCIG)</gtr:description><gtr:id>899E1956-705A-40E5-8D34-5E05FC85454F</gtr:id><gtr:impact>Completion of recruitment of ICON7 trial from over 300 clinical sites in 11 countries. Publication of results from ICON5 trial, a GCIG collaboration with UK, US, Italy, Australia and New Zealand (pub med 19224846). Recruitment to ICON6 trial (currently open in UK and Canada). Recruitment to ICON8 trial (currently open in Korea and UK). International collaboration on clinical trials as outlined in publication 19720905</gtr:impact><gtr:outcomeId>DC83D61439F-1</gtr:outcomeId><gtr:partnerContribution>Collaboration in trials and harmonisation of processes and procedures</gtr:partnerContribution><gtr:piContribution>The Gynecologic Cancer Intergroup is an international collaboration of clinical trialists, whose aims are to promote and conduct high quality clinical trials in order to improve outcomes for women with gynecologic cancer. The MRC CTU contributes strongly to this collaboration with the majority of our trials being badged as GCIG trials. The contributions of this group include providing a forum for discussion on clinical trial development and prioritisation of research questions, harmonisation of clinical trial operations, participation in international clinical trial recruitment and meta-analyses.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London Hospitals Charity (UCLH)</gtr:department><gtr:description>A review of RCTs in recurrent ovarian cancer</gtr:description><gtr:id>D4899D3F-96A4-432A-BD4A-1ABC87B24686</gtr:id><gtr:impact>Protocol in development</gtr:impact><gtr:outcomeId>56cc92b5906697.00803937-1</gtr:outcomeId><gtr:partnerContribution>Reviewed results of searches and early stage protocol development</gtr:partnerContribution><gtr:piContribution>Carried out searches for trials and reviewed the results, early stage protocol development</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EORTC - BR14</gtr:description><gtr:id>7A8165F4-65A3-401D-9329-32B8A36A3AC5</gtr:id><gtr:impact>The trial completed recruitment in 2015.</gtr:impact><gtr:outcomeId>56d984e5744405.89443534-1</gtr:outcomeId><gtr:partnerContribution>Intergroup collaboration has enabled this trial, which is in a relatively rare type of brain tumour to take place. The overall trial co-ordination and sponsorship is taken by the EORTC.</gtr:partnerContribution><gtr:piContribution>The MRC CTU at UCL contributed to statistical design of the study during initial design dicussions and oversees and facilitate UK participant through an intergroup agreement with the EORTC. We are responsbile for ethics and regulatory approval and reporting and UK site management. As a result of our involvement any approved UK site may participate in the trial without this only EORTC member sites would be able to take part substanitally limiting accrual.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scandinavian Sarcoma Group (SSG)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>EURAMOS</gtr:description><gtr:id>F35623BD-E4FF-427E-9AA0-982E30193299</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-3</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Bone Cancer CSG</gtr:department><gtr:description>EURAMOS</gtr:description><gtr:id>99EDCD52-33FA-408B-88E2-CF4BBCD79801</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-7</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EURAMOS</gtr:description><gtr:id>C7A4B7E7-E0CB-44C1-9E1E-4941975F607B</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-8</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>C5458243-0FC6-4880-8D53-95807015ECC1</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-3</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>EA0501B2-441B-4AA5-B4C5-B2AB238E8902</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-4</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gynecologic Cancer InterGroup (GCIG)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>59E59769-5AAB-4252-ACC7-1E79678611DD</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-2</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Canadian Cancer Trials Group</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Canadian (CCTG) collaboration on FOCUS4</gtr:description><gtr:id>52650A37-7C76-4634-864F-6390435BE308</gtr:id><gtr:impact>No outputs as yet as recruitment is to begin in 2017</gtr:impact><gtr:outcomeId>58b9b6c33f0fd5.99213816-1</gtr:outcomeId><gtr:partnerContribution>Beginning in 2017, recruiting patients to FOCUS4</gtr:partnerContribution><gtr:piContribution>Provision of a platform for biomarker stratification and an open trial that becomes the first Canada-wide stratified medicine cancer trial</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Schering Plough</gtr:department><gtr:description>EURAMOS</gtr:description><gtr:id>8D93DD26-9A55-49F5-9FE3-A900BB311AB6</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-5</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Danish Cancer Society</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>RADICALS and Denmark</gtr:description><gtr:id>65C3F2D1-809F-41F9-B4B3-716976310C6F</gtr:id><gtr:impact>Results to follow 2018-2020</gtr:impact><gtr:outcomeId>56e05bf083f959.45527601-1</gtr:outcomeId><gtr:partnerContribution>Danish sites in Copenhagen, Aarhus and elsewhere have collaborated in recruiting, treatment and following-up patients</gtr:partnerContribution><gtr:piContribution>RADICALS trial is led from MRC CTU at UCL</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Research Group on Ovarian Cancer and Gynecologic Tumors of Mexico (GICOM)</gtr:collaboratingOrganisation><gtr:country>Mexico, United Mexican States</gtr:country><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>A76E9D82-2113-4F35-96B5-66D53A484A95</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-6</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alcura</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Add-Aspirin trial - Alcura Ltd</gtr:description><gtr:id>247918BA-F4B3-45BD-A3ED-187109A62CB5</gtr:id><gtr:impact>No outputs yet. The trial is currently in set-up.</gtr:impact><gtr:outcomeId>544e7039a3aca5.17592482-1</gtr:outcomeId><gtr:partnerContribution>Alcura Ltd will package, label and distribute the run-in and blinded Add-Aspirin trial medication to all centres in the UK and India.</gtr:partnerContribution><gtr:piContribution>Following an EU tender, a contract has been agreed with Alcura Ltd to package, label and distribute the run-in and blinded Add-Aspirin trial medication to all centres in the UK and India. Contract negotiations are now close to completion. The trial team have developed an in-house drug supply system which will be accessed to manage packaging and distribution by Alcura Ltd.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Society of Gynaecological Oncology (ESGO)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>European Network of Gynaecological Oncology Trials Groups (ENGOT)</gtr:department><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>DB827C5D-A432-493B-B7CA-2BE37D9CF768</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-3</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial College Trust</gtr:department><gtr:description>PATCH bone biomarker sub-study</gtr:description><gtr:id>1BBCDF27-593C-4310-9C0B-BFC43EA30573</gtr:id><gtr:impact>The proposal is currently in development.</gtr:impact><gtr:outcomeId>56d86e58b05ac6.54918239-1</gtr:outcomeId><gtr:partnerContribution>Dr Richie Abel is leading on the proposal and will coordinate the analysis of the stored serum samples.</gtr:partnerContribution><gtr:piContribution>We are working with Dr Richie Abel, who is a lecturer in Musculoskeletal Sciences, on a proposal to compare changes in bone biomarkers between treatment arms (oestrogen patches vs LHRHa) within the PATCH trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Gynaecological Oncology CSG</gtr:department><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>104C0D80-98D1-416E-BED6-641B8B054793</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-4</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Testis Tumour CSG</gtr:department><gtr:description>TRISST trial</gtr:description><gtr:id>7D1390AC-EF94-404B-987B-CBE15DB8B1B9</gtr:id><gtr:impact>Ongoing.
This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit.</gtr:impact><gtr:outcomeId>XEfdDa9RqPi-1</gtr:outcomeId><gtr:partnerContribution>This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation.</gtr:partnerContribution><gtr:piContribution>Trial design, coordination and analysis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Brain Tumour CSG</gtr:department><gtr:description>BR13 Collaborations</gtr:description><gtr:id>B32F1107-6695-45F9-8148-25643E1E76F7</gtr:id><gtr:impact>The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated.</gtr:impact><gtr:outcomeId>54857f775d68c1.08268351-2</gtr:outcomeId><gtr:partnerContribution>The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis.
The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tata Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Add-Aspirin - Tata Memorial Hospital</gtr:description><gtr:id>2906B611-EC6F-4938-A5C8-495A3D6628BB</gtr:id><gtr:impact>In terms of the Add-Aspirin trial, the collaboration will speed up delivery of the research and enable demonstration of the health intervention in a range of settings, increasing the potential global impact of the results. Additionally, the work is facilitating development of a cancer research network in India and will pave the way for future collaborative projects.</gtr:impact><gtr:outcomeId>5458e65a4a2849.11742898-1</gtr:outcomeId><gtr:partnerContribution>Management and oversight of the Add-Aspirin trial in India.</gtr:partnerContribution><gtr:piContribution>Leading the Add-Aspirin trial; management of the trial in the UK; oversight and mentoring of the research group at the Tata Memorial Hospital who will manage Indian participation in the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>EURAMOS</gtr:description><gtr:id>EAEBA457-1BD7-4B88-B8F2-33B306D72861</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-6</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wales Cancer Bank</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:description>Add-Aspirin - Wales Cancer Bank</gtr:description><gtr:id>1594A27F-8768-44F7-8752-5F8241549EBF</gtr:id><gtr:impact>The sample collection was initiated at the time that the trial opened to recruitment (October 2015) and collection of samples is currently ongoing. Translational work utilising the collection is being planned.</gtr:impact><gtr:outcomeId>56db6efa2ce830.38281814-1</gtr:outcomeId><gtr:partnerContribution>Wales Cancer Bank will host the Add-Aspirin sample collection in the UK (jointly with Tayside Tissue Bank) - receiving, processing and storing biological samples from participating trial sites.</gtr:partnerContribution><gtr:piContribution>We are leading and co-ordinating the Add-Aspirin clinical trial and the associated collection of biological samples from trial participants.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>BR13 Collaborations</gtr:description><gtr:id>EACE35C4-D9F2-4180-AE05-8EE1D81110AD</gtr:id><gtr:impact>The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated.</gtr:impact><gtr:outcomeId>54857f775d68c1.08268351-1</gtr:outcomeId><gtr:partnerContribution>The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis.
The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>PATCH trial Progynova sub-study - Bayer Plc</gtr:description><gtr:id>708F32AD-734D-428E-B838-599505318EC9</gtr:id><gtr:impact>The sub-study opened for enrolment in October 2015.</gtr:impact><gtr:outcomeId>56d868d8507fc1.91899366-1</gtr:outcomeId><gtr:partnerContribution>Bayer Plc will provide the Progynova patches at a 37% discount price, and will ensure the supply of the patches for the sub-study.</gtr:partnerContribution><gtr:piContribution>We approached Bayer Plc to supply the Progynova oestrogen patches for a sub-study within the main PATCH trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>TRISST trial</gtr:description><gtr:id>FEB51059-45BC-4C11-ACB2-BB97C85637A5</gtr:id><gtr:impact>Ongoing.
This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit.</gtr:impact><gtr:outcomeId>XEfdDa9RqPi-2</gtr:outcomeId><gtr:partnerContribution>This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation.</gtr:partnerContribution><gtr:piContribution>Trial design, coordination and analysis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Institute of Canada Clinical Trials Group</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>RADICALS and Canada</gtr:description><gtr:id>214A8B1B-C0E2-4BF0-9ABB-92311C3F8DD1</gtr:id><gtr:impact>Results from the trial will follow on 2018 to 2020</gtr:impact><gtr:outcomeId>56e05c69c5a587.47410199-1</gtr:outcomeId><gtr:partnerContribution>Canadian sites have engaged in recruiting, treating and following-up patients. This has been organised by the Canadian Cancer Trials Group.</gtr:partnerContribution><gtr:piContribution>RADICALS trial is led from MRC CTU at UCL</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Health Economics (CHE)</gtr:department><gtr:description>Collaboration on health economics analysis in TRISST trial</gtr:description><gtr:id>BDFCFB59-A692-4CD3-979D-3C5B9885C791</gtr:id><gtr:impact>No outputs to date.
This is a multi-disciplinary collaboration between the TRISST Trial Management Group - which includes clinicians, statisticians and trialists - and colleagues at York University with expertise in health economics.</gtr:impact><gtr:outcomeId>56daf098138077.07725424-1</gtr:outcomeId><gtr:partnerContribution>Performing health economics analyses for the TRISST clinical trial, alongside the primary (efficacy) analyses</gtr:partnerContribution><gtr:piContribution>Design, conduct and management of the TRISST clinical trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Bartholomew's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Barts Chemotherapy Response Score Collaboration</gtr:description><gtr:id>E68B5E7F-8513-41AA-B349-0A06281C3DDB</gtr:id><gtr:impact>No outputs at present</gtr:impact><gtr:outcomeId>56decbde3f76a7.04696203-1</gtr:outcomeId><gtr:partnerContribution>Validation of CRS system and funding of this project.</gtr:partnerContribution><gtr:piContribution>Organisational input, provision of samples (omental slides) and future corresponding data</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Irish Clinical Oncology Research Group (ICORG)</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>B43BB530-E14C-43C2-A6D2-BA8F03B28CBD</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-8</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sir Dorabji Tata Trust</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Add-Aspirin - Sir Dorabji Tata Trust</gtr:description><gtr:id>D29B908D-86CC-48E1-9D7B-2AC6F98B3E28</gtr:id><gtr:impact>Securing this funding has meant that the Add-Aspirin trial can open in India. Set-up activities are currently underway.</gtr:impact><gtr:outcomeId>56db6d776436f0.96412429-1</gtr:outcomeId><gtr:partnerContribution>The Sir Dorabji Tata Trust has agreed to provide funding to the Tata Memorial Centre to run the Add-Aspirin trial in India.</gtr:partnerContribution><gtr:piContribution>Our team is leading the international Add-Aspirin clinical trial in collaboration with a group at the Tata Memorial Centre who will lead the trial in India.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>9BF3E8C7-4BBB-452D-B29F-5AF92B4F5610</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-2</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Add-Aspirin trial - Bayer Pharmaceuticals PLC</gtr:description><gtr:id>4B84A26E-6AD0-4253-A9FD-D1A3692940BB</gtr:id><gtr:impact>Contract signed, no output to date. The trial is currently in set-up.</gtr:impact><gtr:outcomeId>544e71760bbe94.68921366-1</gtr:outcomeId><gtr:partnerContribution>Bayer Pharmaceuticals are supplying the Add-Aspirin trial medication (100mg aspirin tablets, 300mg aspirin tablets and matched placebos) free of charge.</gtr:partnerContribution><gtr:piContribution>We approached Bayer to supply the drugs for the Add-Aspirin trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TRICON8B</gtr:description><gtr:id>429A7156-2034-4D80-ADEF-6D77117CAD9B</gtr:id><gtr:impact>Establishment of a tissue bank linked to the ICON8 trial</gtr:impact><gtr:outcomeId>56d9b15a5b4267.56512884-1</gtr:outcomeId><gtr:partnerContribution>Collection, handling, storage and preliminary analysis of blood and tissue samples collected from consenting ICON8B patients.</gtr:partnerContribution><gtr:piContribution>We will facilitate entry of patients consenting to the ICON8B trial into the associated translational studies and keep records of samples collected via the Translational Research CRF.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Canadian Cancer Society Research Institute (CCSRI)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>0C7E0676-749C-456E-BCBE-FC7126AABA57</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-1</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Australia and New Zealand Gynaecological Oncology Group (ANZGOG)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>6A6A8B5C-0897-4C81-8BD2-0BD8DD36851D</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-7</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>BR13 Collaborations</gtr:description><gtr:id>D1DE2D27-630A-4902-99AC-0034D161ADE5</gtr:id><gtr:impact>The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated.</gtr:impact><gtr:outcomeId>54857f775d68c1.08268351-3</gtr:outcomeId><gtr:partnerContribution>The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis.
The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca start-up funding toward RAMPART international renal cancer adjuvant trial</gtr:description><gtr:id>4856CA59-0204-4691-93DD-1C15DF89ABDA</gtr:id><gtr:impact>Development of trial underway and in discussion with regulatory authorities</gtr:impact><gtr:outcomeId>58c691f67b30e9.61601654-1</gtr:outcomeId><gtr:partnerContribution>Provision of start-up funds and drug information in support of the planned trial (which will itself have further funding)</gtr:partnerContribution><gtr:piContribution>An international consortium of key investigators in this field and a novel trial design</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Korean Gynaecological Oncology Group</gtr:collaboratingOrganisation><gtr:country>Korea, Republic of</gtr:country><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>5BD12221-0BB6-46EC-9423-3B12CA168539</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-5</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Institute (NCI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Children's Oncology Group (COG)</gtr:department><gtr:description>EURAMOS</gtr:description><gtr:id>ACF5CBC2-C765-4B38-AC15-924C65D0A9E5</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-4</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Clovis Oncology, inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TransMAGIC - CLOVIS</gtr:description><gtr:id>0F3999F6-EB2A-4A09-BBDA-9AE1CD6E8F97</gtr:id><gtr:impact>Collaboration only recently started, so no output yet.</gtr:impact><gtr:outcomeId>56d9969a33afe8.87044096-1</gtr:outcomeId><gtr:partnerContribution>Will be analysing the tumour samples, and performing statistical analysis on the data.</gtr:partnerContribution><gtr:piContribution>Supply of tumour samples and clinical data from MAGIC. At a later date will be involved in reviewing the output of the work.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cooperative Osteosarcoma Study Group (COSS)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EURAMOS</gtr:description><gtr:id>D3602D42-D672-4243-BD1D-815F5D9C815D</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-2</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European and American Osteosarcoma Study Group (EURAMOS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>European Osteosarcoma Group (EOI)</gtr:department><gtr:description>EURAMOS</gtr:description><gtr:id>5D66828E-308B-4C9B-B05A-4A6263141AAD</gtr:id><gtr:impact>No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 
1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting).</gtr:impact><gtr:outcomeId>BCF996E38C8-1</gtr:outcomeId><gtr:partnerContribution>Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough.</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. 
New participants to the group are currently joining.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with AstraZeneca on cedaranib following ICON6 trial outcome</gtr:description><gtr:id>F7BD8E8F-FC90-4C60-8DFD-3C00563AF0D8</gtr:id><gtr:impact>Full study report in development</gtr:impact><gtr:outcomeId>546200ac855937.54748239-1</gtr:outcomeId><gtr:partnerContribution>Drug supply only until positive outcome of the study was reported. Subsequently, close colloaboration on preparation of regulatory package.</gtr:partnerContribution><gtr:piContribution>Sponsored and ran the ICON6 trial after AZ abandoned development of this compound. Now working with them to produce licensing application. Anticipate considerable research support plus drug supply for trials to follow.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ICON8 trial (NCT10356837)</gtr:description><gtr:id>B0AD003E-13AC-4470-9FDA-EF9C9F9D660F</gtr:id><gtr:impact>Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant.</gtr:impact><gtr:outcomeId>KKGvNzUBx72-1</gtr:outcomeId><gtr:partnerContribution>CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally.</gtr:partnerContribution><gtr:piContribution>Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Aspirin trialists collaborative group meeting (Vienna, 2015)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>799DD7B8-C396-47BF-AFBD-2F084EBF5CCE</gtr:id><gtr:impact>This was the initial meeting of a new collaborative group of international researchers leading trials investigating the effects of aspirin in colorectal cancer. The formation of this group is expected to lead to future formal collaborations - for example, on meta-analyses of trial data.</gtr:impact><gtr:outcomeId>56db58eab8cde9.70662678</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin leaflets at the NCRN Clinical Studies Group trials meetings</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>557EBEA0-8795-4A80-9B5A-0C37B2BF8790</gtr:id><gtr:impact>Leaflets about the Add-Aspirin trial were included in delegate packs for the NCRN urological and breast Clinical Studies Group trials meetings early in 2016, and some of the trials unit team attended the meetings. Attendees at the meetings included research teams from sites that were already participating in the trial and some that were going through the set-up process or interested in participating. Thus, it provided an opportunity to engage with these researchers and further raise awareness of the trial.</gtr:impact><gtr:outcomeId>56db6200255568.31928928</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer Patients roadshows</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>90A5DF45-1EC7-4622-BE8F-BD7724390698</gtr:id><gtr:impact>Events across a number of research centres in the UK were organised by Cancer Research UK and the MRC Clinical Trials Unit (CTU) at UCL for men affected by prostate cancer and their families, and there were presentations/stands from some of the trials within the CTU including STAMPEDE and PATCH.</gtr:impact><gtr:outcomeId>58a31d7f209df9.24775326</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRISST patient newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B0EFF911-6B7A-4F85-BECF-756183E8BCCA</gtr:id><gtr:impact>TRISST trial newsletters, containing the latest study news, were distributed to all trial participants via participating centres.</gtr:impact><gtr:outcomeId>56daf784af7148.55573087</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EURAMOS-1 Poor Responders at CTOS 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>83B3E51D-8503-4339-941D-421EEE77766E</gtr:id><gtr:impact>The results of the Poor Response randomisation of the EURAMOS-1 were presented for the first time at the Connective Tissue Oncology Society meeting 2015 in Berlin, Germany, by Neyssa Marina (Stanford, CA, USA), one of the lead clinicians for the trial. The analysis were done and the slides prepared by MRC CTU at UCL.
This will change practice despite not finding in favour of the research arm. A paper was submitted for publication late in 2015.</gtr:impact><gtr:outcomeId>56d883301b15f0.45702647</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 NCRI Stage 1A results</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>63FB77B8-DD47-45BB-B2AD-7C3F94710AB0</gtr:id><gtr:impact>ICON8 Stage 1A results</gtr:impact><gtr:outcomeId>56dda77e456c80.96461600</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ENGOT Vienna 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>64C14627-B81E-4BFA-B475-C2491DB5BDF3</gtr:id><gtr:impact>Trial Update Presentation</gtr:impact><gtr:outcomeId>56dda4b08512c5.06082202</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ENGOT Liverpool 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0DED0947-5866-4B4D-9C46-567AB8BB87B7</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9d6f934639.86023031</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 Launch Meeting 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>74069270-3B66-47C1-AADD-CE835D457FFC</gtr:id><gtr:impact>Trial Launch Meeting</gtr:impact><gtr:outcomeId>56dda4ef9e00f8.53408198</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin presentation at Thames Valley Cancer Research Network event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BFFE0C53-B4B0-46BF-84A9-6A4A971E9C0D</gtr:id><gtr:impact>Professor Langley gave a presentation about the Add-Aspirin trial at the Thames Valley Cancer Research Network away-day. This was an opportunity to engage with research teams at sites that might participate in the trial. Subsequently, a number of sites in this network have opened to recruit to the trial.</gtr:impact><gtr:outcomeId>56db64164cb590.90058120</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>OE05 presentation at ESMO 2015 (Vienna)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50EE6C72-88E5-4F81-B360-BBBFDEE7CF7D</gtr:id><gtr:impact>Further presentation of the OE05 trial results at the European Cancer Congress in Vienna. Lots of discussion regarding the impact of the results on future treatment.</gtr:impact><gtr:outcomeId>56d80a9da4b140.62042504</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ecco-org.eu/Vienna2015</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRICON8B Launch NCRI Glasgow 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8E702AA4-E3A9-420A-8303-5536404C350A</gtr:id><gtr:impact>TRICON8B Launch NCRI Glasgow 2016</gtr:impact><gtr:outcomeId>56ddadacd61224.04726869</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8B Launch Meeting London 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71029B23-D128-4BB2-BC22-3A8553FD5A5A</gtr:id><gtr:impact>ICON8B Trial Launch meeting and training presentation</gtr:impact><gtr:outcomeId>56dd9e3dc23c48.49041466</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 GCIG London 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA1A1A09-1597-45EE-AEB0-5394FA0DF144</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9d50306939.39183863</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ENGOT Frankfurt 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>231F14D8-8600-4140-B870-147542C79F8A</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9d2b090246.29880185</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin oral presentation at ESMO world congress on Gastrointestinal Cancer Conference 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>012DB0B8-AE9D-489F-B762-C3BA14FEA159</gtr:id><gtr:impact>Oral presentation and poster presentation entitled &amp;quot;Are the Benefits of Aspirin in Colorectal Cancer Limited to PIK3CA Mutated Cancers?&amp;quot; at an international conference. The talk promoted discussion and raised awareness of the Add-Aspirin trial.


Promoted discussion</gtr:impact><gtr:outcomeId>544e761ac56671.00319616</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://annonc.oxfordjournals.org/content/25/suppl_2/ii109.3.short</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin website</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>362CEFB5-6CB3-430E-8D45-1DBD4198A1D0</gtr:id><gtr:impact>The Add-Aspirin clinical trial website has been designed to provide information and updates about the trial to study participants, research teams at participating trial sites, other research groups and the general public.</gtr:impact><gtr:outcomeId>56db7324e0b379.11166309</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:url>http://www.addaspirintrial.org</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin interview for BBC World TV</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AF24E71B-7534-4D1A-8DCC-E7D7BDD439AF</gtr:id><gtr:impact>Professor Langley gave an interview for BBC World TV about the launch of the Add-Aspirin clinical trial. The launch was picked up by the news media internationally and prompted requests for further information, both from the general public and from other research groups.</gtr:impact><gtr:outcomeId>56db6917baec86.21013871</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC CTU at UCL joint urological trials regional meetings</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5237D627-D816-4EBC-A36C-69DC90813CCB</gtr:id><gtr:impact>Four regional meetings were held in London, Bristol, Liverpool and Glasgow, with presentations from urological trials being conducted with the unit including PATCH, SORCE, RAMPART, STAMPEDE, RADICALS, Add-Aspirin, TRISST and PROMIS. As well as staff from participating sites, there were also patient representatives from the trials, and staff from Cancer Research UK, Prostate Cancer UK, and NIHR Clinical Research Network.</gtr:impact><gtr:outcomeId>58a31944d7e150.63483196</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin interview in The Observer</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C7B0F5E7-2939-498C-B585-9F15EFEF6F85</gtr:id><gtr:impact>Interview regarding the Add-Aspirin trial included in an article in The Observer</gtr:impact><gtr:outcomeId>58b6d73af21de6.24774449</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.theguardian.com/science/2016/jun/12/anti-cancer-drugs-medicine-cabinet-repurposed-aspirin-thalidomide-beta-blockers</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 GCIG Stage 1A results</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>66E2238C-F463-48CA-BF5E-4ED91E45EE7A</gtr:id><gtr:impact>ICON8 GCIG Stage 1A results</gtr:impact><gtr:outcomeId>56dda74f125e91.19645652</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 GCIG Tokyo 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E4201708-5306-4BD4-BD56-AE14D8CD8A6E</gtr:id><gtr:impact>Trial update</gtr:impact><gtr:outcomeId>56dd9b996f26f3.67653419</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ENGOT Nice 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3B1E525A-2C2A-43D3-B010-B93950290513</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9c745f00a9.83368842</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ENGOT Madrid 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>682FDDC1-8A54-4FF3-A324-60327C357707</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9ce1b81648.62939406</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin methodology seminar at ICR CTSU</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2D490243-9AC4-492C-8EED-9F171F8482CC</gtr:id><gtr:impact>Invited to give a trials methodology seminar at the Institute of Cancer Research clinical trials unit covering novel aspects in the design and conduct of the Add-Aspirin trial. The talk prompted some interesting discussions and is expected to lead to future sharing of knowledge and experience between the two trials units.</gtr:impact><gtr:outcomeId>56db534b4f8663.87218156</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8B Feedback Session 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DAB6CAE9-8572-4FF8-9C7C-15047D0C35BE</gtr:id><gtr:impact>Feedback meeting with patient representatives, research nurses and data managers to gain feedback on ICON8B patient documents, trial protocol and CRFs</gtr:impact><gtr:outcomeId>56dd9eb6232eb7.30727149</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 GCIG Melbourne 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D539D4E8-DE22-405E-8E20-0275CFE38E51</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9cbf1a1594.99186151</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PATCH presentation at a monthly Prostate Cancer UK meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CAE22BDA-DEF1-49E9-933A-7A5E7E7ED115</gtr:id><gtr:impact>A brief presentation about the PATCH trials was given followed by questions from the attendees at the meeting, who comprised of communication officers and nurses who take phone calls from patients for Prostrate Cancer UK. The main aims were to inform the group about the study, and to discuss potential ways we can engage with them to help disseminate relevant information to patients and other healthcare professionals.</gtr:impact><gtr:outcomeId>56dde70607c955.79191185</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PPI workshop (Add-Aspirin)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D6F4A029-2AA4-4D9B-AB2F-F0B366DD3CA2</gtr:id><gtr:impact>Involvement in teaching on a workshop about Patient and Public Involvement (PPI) in trials - sharing experiences from the Add-Aspirin trial. The workshop was primarily focused at people working in clinical trials. Participants were engaged and took away new ideas about how best to go about involving patients and the public in their research.</gtr:impact><gtr:outcomeId>56db54e7671815.73816899</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quartz presentation at BTOG 2016 (Dublin)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>867C7EC2-C023-4C32-B11D-2B0130AE7B14</gtr:id><gtr:impact>Invited presentation at BTOG conference in Dublin, discussing the impact of the Quartz results on the general treatment of patients with brain metastases.</gtr:impact><gtr:outcomeId>56d8090367cd33.52375097</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.btog.org/editorimages/BTOG%202016%20Programme%20FINAL4.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quartz presentations at Best of ASCO 2015 (Boston, Chicago and San Francisco)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>70ADB430-A911-41E6-B9AB-243D2B6C11C6</gtr:id><gtr:impact>Following the trial presentation at the main ASCO meeting, it was selected to be presented at the &amp;quot;Best of&amp;quot; ASCO meetings held in the US. Presentations weren't made by members of the trial team.</gtr:impact><gtr:outcomeId>56d80e0b143c14.76148642</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://boa.asco.org/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EURAMOS-1 surgery data: oral presentation at ISOLS 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B02A84A6-A286-4259-A11F-F08092FFCD18</gtr:id><gtr:impact>Data on surgery in EURAMOS-1 trial were presented orally at the International Society Of Limb Salvage meeting 2015 in Florida, USA. The presentation was given by surgeon Rob Grimer. The analyses were led by, and slides prepared by, MRC CTU at UCL.</gtr:impact><gtr:outcomeId>56d88467130d57.72667928</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ESGO Stage 1A results</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5BA35B39-E851-43D7-8FD1-D234B679ADC9</gtr:id><gtr:impact>ICON8 Stage 1A results</gtr:impact><gtr:outcomeId>56dda7a22feed8.34258423</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>OE05 presentation at ASCO 2015 (Chicago)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AE0B2E3B-49A5-4256-AE0D-D92F25EC5CED</gtr:id><gtr:impact>First presentation of OE05 trial results at ASCO conference in Chicago, US. Talk generated lots of discussion about the agents involved and the implications for future treatment.</gtr:impact><gtr:outcomeId>56d809ba1f92a8.88598986</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://meetinglibrary.asco.org/content/149773-156</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EURAMOS-1 Overview at NCRI 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8BBB1DD7-4A5D-4094-9C5F-6C4DA002877C</gtr:id><gtr:impact>Presentation of EURAMOS-1 design, results (particularly Poor Response randomisation) and implications at UK National Cancer Research Institute 2015 conference by Jeremy Whelan (UCL, London). This was an invited talk to a session on clinical trials in rare cancers.</gtr:impact><gtr:outcomeId>56d9543d9d1770.94255560</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate cancer trials poster presentation at the British Association of Urological Surgeons Autumn Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10C26FCF-E541-4B72-98AD-0C30FFDBE119</gtr:id><gtr:impact>A poster was presented summarising the prostate cancer trials coordinated at the MRC Clinical Trials Unit at UCL which are currently recruiting patients (PATCH, STAMPEDE, RADICALS, and Add-Aspirin). This was intended to help clarify the patients eligible for each trials, in terms of clinical pathways.</gtr:impact><gtr:outcomeId>56b9d7e1ea5561.49802122</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI London 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>018899B4-2D0C-4D0C-992F-5C6A13E97D92</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dec9b3987147.71248231</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 ASCO 2014 Poster</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6B6A4EC0-A817-46F2-AC9C-A6A8E145A69D</gtr:id><gtr:impact>Poster presenting an update to the ICON8 trial at ASCO 2014</gtr:impact><gtr:outcomeId>56dda83025f9f0.01035164</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin trial training events for participating site teams</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE1D152E-2661-4023-9FC0-BCBEBD373C90</gtr:id><gtr:impact>Prior to opening the Add-Aspirin clinical trial, two training events were held (in London and in Edinburgh) which were designed to provide teams from participating sites information about the trial and guidance on running it at their site. Attendees included Research Nurses, Trial Co-ordinators, Pharmacists and Clinicians. Other similar training sessions were held via WebEx, reaching staff at more than 100 sites expecting to participate in the trial. Most attendees have subsequently completed the trial set-up process and opened their site to recruit to the trial.</gtr:impact><gtr:outcomeId>56db5e4895ce15.36216784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trial Management Group Meeting- Patient and Public Involvement</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B8978BFC-9E9F-43A1-AC3B-00E36CF1A143</gtr:id><gtr:impact>A patient representative is invited to attend every ICON8/ICON8B Trial Management Group meeting (held 3 monthly). We have 3 patient representatives that are members of our gynaecological oncology Trial Management Groups.</gtr:impact><gtr:outcomeId>588f62b87826f5.44541348</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EURAMOS good responders lay summary</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5484C808-C2FB-496B-9EFF-9AF26735D703</gtr:id><gtr:impact>Lay summary of trial results (First results of the EURAMOS-1: Information for trial participants and families) was prepared and made available via the trial website and sent to investigators to give to participants.

Unknown</gtr:impact><gtr:outcomeId>Y4qSvxFcYA8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.euramos.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin press releases for trial launch</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A745EB51-B3B1-482D-ABE2-2C810E16BC0C</gtr:id><gtr:impact>A national press release, and a number of regional releases, were published to announce the launch of the Add-Aspirin clinical trial. The release was picked up by the news media internationally and prompted a number of requests for interviews from the media and requests for further information about the trial from both the general public and other research groups.</gtr:impact><gtr:outcomeId>56db66c8ec96f2.67078912</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2015-10-22-worlds-largest-clinical-trial-on-aspirin-to-stop-cancer-returning-launches-today</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin interview for Today Programme</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3BF2460F-16EC-4DA7-830F-D378F41EDA33</gtr:id><gtr:impact>Professor Langley gave a radio interview for the Today Programme about the launch of the Add-Aspirin clinical trial. The launch was picked up by the news media internationally and prompted requests for further information about the trial from both the general public and other research groups.</gtr:impact><gtr:outcomeId>56db683824b198.36841222</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 GCIG Chicago 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F92B13EC-26CB-4ED4-9195-ACFE8AD82E6C</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9d06505a20.94132409</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8B Launch Meeting Glasgow 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B5220411-C5EB-4A28-B34C-0DD50511FC6E</gtr:id><gtr:impact>Trial launch meeting and training presentation</gtr:impact><gtr:outcomeId>56dd9e0c586a14.88312377</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin posters at BAUS meetings</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>56C561A8-FBF3-45F0-AA3F-7B06950B5D10</gtr:id><gtr:impact>Posters on the Add-Aspirin clinical trial were displayed at the British Association of Urological Surgeons annual scientific meeting and annual meeting in June and November 2015. The posters were designed to raise awareness of the trial amongst this community who will play a key role in recruitment to the prostate cancer cohort of the trial.</gtr:impact><gtr:outcomeId>56db603e576944.24838013</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ovarian CSG Meeting Dec 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>011CD667-B937-454E-9161-363263DA4F6E</gtr:id><gtr:impact>Trial Update presentation</gtr:impact><gtr:outcomeId>56deca4e0e1e67.81314066</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 GCIG Chicago 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB68ADD7-946E-4A8F-BFEB-1D2DDA615A70</gtr:id><gtr:impact>Trial update presentation</gtr:impact><gtr:outcomeId>56dd9ca0cd31d6.53588804</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICON8 NCRI Poster</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6511C50B-C039-4C59-8F69-B6E7BF279178</gtr:id><gtr:impact>Poster: Current delays in setting-up investigator-driven randomised controlled trials: the MRC ICON8 experience</gtr:impact><gtr:outcomeId>56dda897360576.95559213</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quartz presentation at ASCO 2015 (Chicago)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3D4D374D-638C-4973-A6D0-EBC91F561687</gtr:id><gtr:impact>Main results of Quartz trial presented for the first time at ASCO conference. Involved a large audience, and generated lots of questions/discussion.</gtr:impact><gtr:outcomeId>56d8062edff6e1.25402106</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://meetinglibrary.asco.org/content/149588-156</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PATCH trial information stall at the NCRI Urological CSGs Trials Meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>00796641-5654-48A0-ACF8-5AB06EB21A3A</gtr:id><gtr:impact>Stall showing information on the PATCH trial, including publications, for attendees at the meeting.</gtr:impact><gtr:outcomeId>56b9db0d059d13.47246665</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EURAMOS-1 surgery data: oral presentation at CTOS 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>47EF4AFE-0DFA-4547-88E9-10F7CB22BC5C</gtr:id><gtr:impact>Data on surgery in EURAMOS-1 trial were presented orally at the Connective Tissue Oncology Society meeting 2015 in Salt Lake City, UT, USA. The presentation was given by surgeon Rob Grimer. The analyses were led by, and slides prepared by, MRC CTU at UCL.</gtr:impact><gtr:outcomeId>56d88409067552.05215465</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Overview of EURAMOS-1 trial at BSG 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0233C2F9-B295-43F0-B975-91167C156BED</gtr:id><gtr:impact>Presentation by Matt Sydes at the British Sarcoma Group 2015 national conference in Nottingham 2015. The presentation gave an overview of the whole of the EURAMOS-1 trial to the appropriate clinical audience. This is the main national sarcoma conference for the UK.</gtr:impact><gtr:outcomeId>56d8860639ae90.34705869</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quartz presentation NCRI 2015 (Liverpool)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BD9DA0E-C08E-4AC3-83FF-5F4793FE3FE5</gtr:id><gtr:impact>Presentation of Quartz results at NCRI conference, to a largely UK audience.</gtr:impact><gtr:outcomeId>56d806e62495d3.74311714</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://conference.ncri.org.uk/wp-content/uploads/2015/11/NCRI-2015-Programme.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quartz presentation at World Lung 2015 (Denver)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>818458C7-259D-4893-82C2-5CBB939FC2B9</gtr:id><gtr:impact>Further presentation of Quartz results at World Lung conference in Denver, US. Several questions raised afterwards.</gtr:impact><gtr:outcomeId>56d8086da4fe55.94929495</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.iaslc.org/events/16th-world-conference-lung-cancer</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin trial launch meeting at NCRI conference Liverpool 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>406D6DAC-084B-4352-8BB7-36AE8E1F1FC9</gtr:id><gtr:impact>Add-Aspirin trial launch meeting- Trial promotion and training for research nurses and doctors hoping to participate in the trial at their site.

Increased requests for further information from sites interested in participating in the trial.</gtr:impact><gtr:outcomeId>544e76c742aaa0.07118167</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin poster at the American Society of Clinical Oncology (ASCO) annual meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8B0F1432-391B-444A-9F6D-98F27E131F3E</gtr:id><gtr:impact>Poster presented at the largest oncology conference worldwide to raise awareness and promote interest in the Add-Aspirin trial: &amp;quot;Add-Aspirin Trial: A phase III, double blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours&amp;quot;.

Trial promotion and discussion with international experts</gtr:impact><gtr:outcomeId>544e7345003476.04595416</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>poster presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1617</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>694715</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>FKP</gtr:currCode><gtr:description>AstraZeneca support for start-up of RAMPART renal cancer adjuvant trial</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>759B3E44-55CB-4E6C-815A-A0469F0EAC10</gtr:id><gtr:outcomeId>58c40dd6eb89f9.88807544</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3124812</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR (HTA) funding for Add-Aspirin</gtr:description><gtr:end>2023-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/01/38</gtr:fundingRef><gtr:id>986EE1FF-CCD4-4866-9E06-CDE381A324BE</gtr:id><gtr:outcomeId>544fd08eb01df4.84468746</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>404910</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CTAAC funding for Add-Aspirin sample collection</gtr:description><gtr:end>2025-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C471/A19252</gtr:fundingRef><gtr:id>A7CC664B-3767-4D8F-BCE3-424A0F1EFE47</gtr:id><gtr:outcomeId>56db71c9c5e4d9.17542865</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Science Foundation funding for EURAMOS-1 --&amp;gt; U122861384 (one of many co-funders for many destinations --&amp;gt; approx UK total shown)</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Science Foundation (ESF)</gtr:fundingOrg><gtr:fundingRef>CRUK/06/019 [A3804] - Cancer Research UK seems to consider this as one with the original grant. We did not expect this.</gtr:fundingRef><gtr:id>15C62AF8-5BFA-4CB2-84CD-A547748C3DF6</gtr:id><gtr:outcomeId>ALYurbETapB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>228700</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Committee - funding extension for TRISST trial</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C17084/A8690</gtr:fundingRef><gtr:id>D4C7712E-26BF-4295-AF6F-07639D221907</gtr:id><gtr:outcomeId>58aed44a465d19.93883866</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC trial funding grant for EURAMOS-1 --&amp;gt; U122861384 (one of many co-funders for many destinations --&amp;gt; approx UK total shown)</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>32669585-FD53-4309-AAA2-5A25CC12731B</gtr:id><gtr:outcomeId>WnyFNiZSrs80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1786862</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>PROMIS trial</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>09/22/67</gtr:fundingRef><gtr:id>83AE20BF-6545-4A8F-BDF2-DCF9DB618DB5</gtr:id><gtr:outcomeId>56dc40f8412885.50252253</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer Charity -- RT01/PR07/The Prostate Cancer Charity, UK (via Institute of Cancer Research)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>4C616CA7-71A4-45FD-98F3-6FBA1A5C648A</gtr:id><gtr:outcomeId>sKxb9okBks90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK / CTAAC funding for EURAMOS-1 --&amp;gt; U122861384 (one of many co-funders for many destinations --&amp;gt; approx UK total shown)</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>0AB1FE7F-F887-432D-AA11-E6CC8D273543</gtr:id><gtr:outcomeId>Wy6Jp3NX5T30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3598674</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>CTAAC Clinical Trials Advisory &amp; Awards</gtr:department><gtr:description>CTAAC funding for Add-Aspirin</gtr:description><gtr:end>2023-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C471/A15015</gtr:fundingRef><gtr:id>78B8E2E1-6DCB-42B6-8181-FCFCF2889D75</gtr:id><gtr:outcomeId>544fd0454abde4.68788171</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1288426</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CTAAC funding for PATCH extension</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C17093/A12443</gtr:fundingRef><gtr:id>C6D0BAAD-2F9D-4D1B-86DC-0B6471246C3E</gtr:id><gtr:outcomeId>5444e1fbe79a62.17990288</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCMB guideline 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Evidence-based recommendations for the management of non-small cell lung cancer (NSCLC)</gtr:guidelineTitle><gtr:id>01A83672-A43D-4090-A457-C32C4B609BD2</gtr:id><gtr:impact>&amp;quot;There is level I evidence for patients to receive platinum-based post-surgical adjuvant chemotherapy in II and IIIA NSCLC&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf3338e18fd4.54148010</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2015 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>9278A6B1-5B2F-4C19-8816-2690338D9D3B</gtr:id><gtr:impact>&amp;quot;The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9400508)</gtr:impact><gtr:outcomeId>56d03cdd7e4ae9.05151267</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2017 Cervical Cancer</gtr:guidelineTitle><gtr:id>BA56222F-3BB5-4675-B97C-0994A850A7A2</gtr:id><gtr:outcomeId>58b43414617ad9.59125837</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>C7451877-344C-4F95-B927-DF6F52854D6F</gtr:id><gtr:outcomeId>58b5430f441833.76649270</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III GoodPS inoperable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?</gtr:guidelineTitle><gtr:id>7FEE60EF-37BB-4B57-9686-43339E4D20DC</gtr:id><gtr:outcomeId>58b54a5905e660.31499949</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17636828) CCA guideline stage III Adj CT operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>315686FE-1FF2-437E-8A10-0A3EAA67F79C</gtr:id><gtr:outcomeId>58b44b731d5168.97227644</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524, PMID: 12801735) SEOM guideline 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of invasive bladder cancer (2016)</gtr:guidelineTitle><gtr:id>BA66626A-A450-4D1F-AB04-9A75B749CE22</gtr:id><gtr:outcomeId>58b42ddc2b4836.75736961</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17636828) CCA guideline stage III Adj CT operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>BC986934-1A73-45A6-8397-DC80C8D43248</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17636828)</gtr:impact><gtr:outcomeId>56cf35548035c9.98147776</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2016</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>0E83AD78-375C-4CA1-9C77-8D9F0FAB835F</gtr:id><gtr:outcomeId>58b42c76e14be9.53459906</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer: What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?</gtr:guidelineTitle><gtr:id>783A361E-44BC-4070-A885-251F65393BD6</gtr:id><gtr:outcomeId>58b44972911928.82781204</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404; 15603857) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>9AAA6781-6DA0-46FE-A2D0-FE23532B8D74</gtr:id><gtr:outcomeId>58b44a3d99b1a9.31441745</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2015 Central Nervous System Cancers</gtr:guidelineTitle><gtr:id>6F831734-33FB-440A-B22A-41DA7A885FDF</gtr:id><gtr:impact>&amp;quot;In contrast, 2 meta-analyses reviewed data from randomized trials of high-grade glioma patients, and both found a modest survival benefit when chemotherapy was added to postoperative RT. Specifically, the Glioma Meta- Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative RT (HR, 0.85; 95% CI, 0.78- 0.91; P &amp;lt; .0001)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>56cef1bd8edc67.50201050</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2015 Colon Cancer</gtr:guidelineTitle><gtr:id>D7878DF8-146A-4040-A420-91FCF247DF63</gtr:id><gtr:impact>&amp;quot;A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 22118887)</gtr:impact><gtr:outcomeId>56ceef31d13473.75289411</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>1BFE838B-07DF-47C3-8151-1B3A80D4A60C</gtr:id><gtr:impact>&amp;quot;Neoadjuvant cisplatin-containing combination chemotherapy improves OS (5-8% at 5 years)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>56cecb09b62653.96558529</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15846746) NICE guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NICE Guideline 2: Bladder cancer diagnosis and management</gtr:guidelineTitle><gtr:id>0D2F3C5D-BF69-41FD-AB77-ED8FE0EECD86</gtr:id><gtr:impact>&amp;quot;One systematic review and meta-analysis of individual patient data (3,005 patients from 11 randomised trials) was identified (Advanced Bladder Cancer Meta-Analysis Collaboration (ABC), 2004). No other randomised trials were identified. High quality evidence about overall survival came from 10 trials with a total of 2,809 patients&amp;quot;.....Recommendation: &amp;quot;Offer neoadjuvant chemotherapy using a cisplatin combination regimen before radical cystectomy or radical radiotherapy to people with newly diagnosed muscle-invasive urothelial bladder cancer for whom cisplatin-based chemotherapy is suitable. Ensure that they have an opportunity to discuss the risks and benefits with an oncologist who treats bladder cancer.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15846746)</gtr:impact><gtr:outcomeId>56cecd46023eb9.63707833</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:25730344)(PMID: 20338628) CCA guideline stage II CT after operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Lung Adj CT IPD (PMID:25730344)(PMID: 20338628) CCA guideline stage II CT after operable 2016</gtr:guidelineTitle><gtr:id>434148B0-B2C0-4C15-B57C-E8AF6CE65286</gtr:id><gtr:outcomeId>58b54812044e56.80677504</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?</gtr:guidelineTitle><gtr:id>2264ABEC-4848-4C94-90DB-F2D6DC1BB6A9</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327)</gtr:impact><gtr:outcomeId>56cf40acda8bc7.01640800</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III NeoAdj CT operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>9C585DD6-73AC-4450-9223-7CE3628A0AAB</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)</gtr:impact><gtr:outcomeId>56cef424ce16c2.81519000</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage IV 1stLineCT inoperable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?</gtr:guidelineTitle><gtr:id>367B45D4-533E-4024-8BBE-343D3B3243EA</gtr:id><gtr:outcomeId>58b44869e51659.86320258</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2017. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>70F16BF4-2FD7-43D7-96E1-DAD4AAC35DAC</gtr:id><gtr:outcomeId>58b4395e55c274.94567874</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2015 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>2B5B8FD4-8095-4EAC-A5AA-CB52BE828615</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)</gtr:impact><gtr:outcomeId>56d03d4c9a8225.69943573</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2016. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>82C6023D-B287-48A7-95D5-1878FFCAA1F0</gtr:id><gtr:impact>&amp;quot;Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>56d03e81beef01.30666092</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 3.2015 Esophageal and Esophagogastric Junction Cancers</gtr:guidelineTitle><gtr:id>D30E552D-B1DE-4666-927F-4FAE64C2EC24</gtr:id><gtr:impact>&amp;quot;A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation&amp;quot;, based on our systematic review and meta-analysis of IPD. (PMID: 9635705)</gtr:impact><gtr:outcomeId>56d03c94d49084.29714726</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17636828) CCA guideline stage III NeoAdj CT operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>FE28D7FB-6F9E-494A-8B6C-E230BF176C74</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17636828)</gtr:impact><gtr:outcomeId>56cf3638d585d5.45817353</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID: 16625650) NICE guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NICE Guideline 2: Bladder cancer diagnosis and management</gtr:guidelineTitle><gtr:id>1A6652E4-3B64-4264-A0C3-689519DB9564</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 16625650)</gtr:impact><gtr:outcomeId>56cddf6fda22a0.99410993</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?</gtr:guidelineTitle><gtr:id>2A0C5728-D33F-42AA-AF1A-E10315EFF7F4</gtr:id><gtr:outcomeId>58b54a1bc06b62.55161543</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT resected 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?</gtr:guidelineTitle><gtr:id>2547F5C7-98DA-4572-A551-08BB9ACD2642</gtr:id><gtr:outcomeId>58b44a062f7c30.76780232</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:16235286) GGPO guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Leitlinienprogramm onkologie. Diagnostik und therapie des &amp;Ouml;sophaguskarzinoms v1.0 2015</gtr:guidelineTitle><gtr:id>BD6AFD1B-A6BC-4494-A6E9-417D581CEA86</gtr:id><gtr:impact>&amp;quot;Eine alleinige pr&amp;auml;operative Strahlentherapie kann beim operablen Patienten mit einem resektablen &amp;Ouml;sophaguskarzinom nicht empfohlen werden.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 16235286)</gtr:impact><gtr:outcomeId>56d0357d197bb6.25110430</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2016 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>184FD94C-950D-4DDF-BA91-430E387B56DA</gtr:id><gtr:impact>&amp;quot;The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9400508)</gtr:impact><gtr:outcomeId>56d04296a4e133.26468376</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17636828) SEOM guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015</gtr:guidelineTitle><gtr:id>D6C67AB6-49EE-4908-8A4E-EB7BC8E6A1FA</gtr:id><gtr:impact>&amp;quot;The Cochrane meta-analysis demonstrated that preoperative therapy is better than surgery alone for patients with stage III&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17636828)</gtr:impact><gtr:outcomeId>56cf369a983587.10663853</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>F1887DC1-6FF0-41AE-B10D-B547F9CB2DA4</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20464750)</gtr:impact><gtr:outcomeId>56cf3fda3ecf64.46607762</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of Psycho-social oncology and survivorship NCRI CSG</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>301AF01E-9A7F-4603-AF01-FED59F681CF9</gtr:id><gtr:outcomeId>58bd41b28423f7.24633505</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:23235641) AHS guideline 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer of the Uterine Cervix</gtr:guidelineTitle><gtr:id>CAC62700-F047-4196-8083-90F386C16200</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 23235641)</gtr:impact><gtr:outcomeId>56ced4af8dce86.42828200</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage III Adj CT operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>0549C5F7-488D-4D3F-8EC2-3B0286794862</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf31937479e9.52135293</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2016</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>EAAD506A-36FE-4131-9DA5-2B6BA55133B6</gtr:id><gtr:outcomeId>58b4319d763a57.42954720</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2016 Cervical Cancer</gtr:guidelineTitle><gtr:id>933D4CAB-FC7F-4BD8-89CF-F2B6B466E5B0</gtr:id><gtr:impact>&amp;quot;A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; P &amp;lt;.001)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>56d03d9ddf0c48.06316971</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III NeoAdj CT operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>B7918CC5-7EAB-4636-B660-F4D904FD43DF</gtr:id><gtr:outcomeId>58b5477aa947d3.15062104</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.2.2015 Cervical Cancer</gtr:guidelineTitle><gtr:id>DBC7F304-62E8-416D-AC31-69DF310E1F93</gtr:id><gtr:impact>&amp;quot;Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 20091632)</gtr:impact><gtr:outcomeId>56ced10342fc42.52596323</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage III GoodPS inoperable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?</gtr:guidelineTitle><gtr:id>37F407CE-BD34-4019-9487-2AE307534EB1</gtr:id><gtr:impact>&amp;quot;In good performance status patients with inoperable stage III NSCLC, the addition of chemotherapy to radiation therapy is associated with a statistically significant survival benefit compared with radiation therapy alone&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf31f90a4420.84856366</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>201CC8C4-532B-4E31-B7E0-F22B2E168704</gtr:id><gtr:outcomeId>58b44aeb5acbc9.09329394</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>5EC329BE-4370-4861-9FC7-20809E7550C7</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>56cf379a638bd8.73989493</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2017 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>1E84CAFA-BB7C-4F82-9129-E08F9F7C4A63</gtr:id><gtr:outcomeId>58b54c1e57d6f1.63385043</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2017 Cervical Cancer</gtr:guidelineTitle><gtr:id>F2049C8D-D809-4C79-9075-DA72E792A04D</gtr:id><gtr:outcomeId>58b4335f9287d3.86157746</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>67CE3D04-F1C7-4EEA-9433-B753919F0B8F</gtr:id><gtr:outcomeId>58b54abd8b8a37.26817203</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) ASTRO guideline Def Adj RT 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline</gtr:guidelineTitle><gtr:id>05948E21-5EB0-404C-97CF-49E38CE571D8</gtr:id><gtr:impact>&amp;quot;Currently, adjuvant CT has become the standard of care for patients with completely resected stage II and III NSCLC, after the results from multiple randomized trials, later validated by meta-analyses,demonstrated that addition of platinum-based CT after resection of LA NSCLC leads to absolute overall survival improvements at 5 years of between 5% and 15%&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>56cf09269d8472.17851607</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT IPD (PMID: 24576776) CCA guideline stage III NeoAdj CT operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>3C84EF1C-14FA-4BB0-B5B6-DA5E9D774ACF</gtr:id><gtr:impact>&amp;quot;In patients with clinical stage IIIA disease treated by surgery, neoadjuvant chemotherapy reduces the relative risk of death by 13%, and improves absolute 5 year survival rates from 20 to 25%&amp;quot;; &amp;quot;It is recommended to consider pre-operative administration of 2-3 cycles of platinum doublet-based, third-generation chemotherapy as a treatment option in good performance status patients with operable clinical stage IIIA non-small cell lung cancer.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cf34766a0f87.68619476</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>0DE99158-3F01-420F-942E-0531A0142E8E</gtr:id><gtr:impact>&amp;quot;The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab- 2a, N1; 2) T2b, N1; or 3) T3, N0 disease&amp;quot;...&amp;quot;Postoperative adjuvant sequential chemotherapy with RT is recommended for patients with T1-3, N2 disease and negative margins . A meta-analysis assessed postoperative chemotherapy with (or without) postoperative RT in patients mainly with stage III disease.675 In this meta-analysis, 70% of the eligible trials used adjuvant chemotherapy before RT; 30% used concurrent chemo/RT. Regimens included cisplatin/vinorelbine followed by RT or concurrent cisplatin/etoposide.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>56d03f53ce0232.67332092</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) CCA guideline stage III PORT resected 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?</gtr:guidelineTitle><gtr:id>2808DC45-2903-40F3-92FF-93577EA30EF1</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)</gtr:impact><gtr:outcomeId>56cef52cc36816.62356788</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>3B7B6E6E-2F02-420B-BF96-C42152E3DC28</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530)</gtr:impact><gtr:outcomeId>56cde946e72f90.44945864</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III GoodPS inoperable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?</gtr:guidelineTitle><gtr:id>286A593A-B49E-4087-A747-19045E05953C</gtr:id><gtr:impact>&amp;quot;For patients with good performance status and inoperable stage III NSCLC, the concurrent administration of chemotherapy and radiotherapy is recommended.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>56cf4104af4601.09116813</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) CCA guideline stage II CT after operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>CEC5A2D1-F9A2-489F-B49B-0CD0DF222CA7</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)</gtr:impact><gtr:outcomeId>56cef4b62dc372.36728153</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 20464750) ASCO guideline systemic Stage IV 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update</gtr:guidelineTitle><gtr:id>CB6D728B-137E-4D56-8C00-DB391993A227</gtr:id><gtr:impact>&amp;quot;Cochrane systematic review on chemotherapy and supportive care... continued to show that chemotherapy and best supportive care versus supportive care alone benefit patients, including those who have PS 2&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20464750)</gtr:impact><gtr:outcomeId>56cf3f82e781a2.58563231</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>B4F232A3-4BD0-48EE-8D10-731FC9A3AF0C</gtr:id><gtr:impact>&amp;quot;PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 9690404)</gtr:impact><gtr:outcomeId>56d04082befc63.88780977</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:23235641) AHS guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline</gtr:guidelineTitle><gtr:id>DF8C9CB1-6A12-4605-8D3D-39FC838A081B</gtr:id><gtr:outcomeId>58b433ce895081.13857490</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015</gtr:guidelineTitle><gtr:id>ED55E9C2-725C-43C0-BD36-CDAA19EDB40B</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327)</gtr:impact><gtr:outcomeId>56cf41c1aa8554.98930353</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 20464750) CCA guideline stage IV 1stLineCT inoperable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?</gtr:guidelineTitle><gtr:id>F8BCADE6-05EE-4160-A443-0580B46D6784</gtr:id><gtr:outcomeId>58b54462d42251.10327101</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Bladder Cancer</gtr:guidelineTitle><gtr:id>1863D7E0-6F19-40DE-B725-CC9CBC605A81</gtr:id><gtr:outcomeId>58b431e573a8c3.90619804</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>C96B28F7-D69F-4419-BCFA-F2E94685AFF7</gtr:id><gtr:outcomeId>58b44926c17df0.32141947</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 20464750) CCA guideline stage IV 1stLineCT inoperable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?</gtr:guidelineTitle><gtr:id>1ED0CE47-53B7-4878-8C66-6AE3994482A4</gtr:id><gtr:impact>&amp;quot;Platinum-based chemotherapy improves survival in stage IV NSCLC compared with best supportive care. Note that this evidence is based on clinical trials conducted in fit patients, with predominant performance status 0-1, no unstable co-morbidities, adequate organ function and without uncontrolled brain metastases.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20464750)</gtr:impact><gtr:outcomeId>56cf404d494c70.62709417</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>2C6B1034-5B97-437B-8EE3-12A5E9716D35</gtr:id><gtr:impact>&amp;quot;The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab- 2a, N1; 2) T2b, N1; or 3) T3, N0 disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>56cf09ea952e80.54677450</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) AHS guideline 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer of the Uterine Cervix</gtr:guidelineTitle><gtr:id>F558097D-C7C4-46BA-91FA-793E27F4F36A</gtr:id><gtr:impact>&amp;quot;Medically fit patients with advanced stage cervical cancer (stage IB2/IIB/IIIA/IIIB/IVA), as well as select stage IIA cases, should be considered for treatment with concurrent radiotherapy and chemotherapy.8,10,13,18 A meta-analysis of 13 trials showed that chemoradiotherapy (versus radiotherapy alone) increased the disease free survival rate at five years by eight percent.17 There was a significant trend towards increased overall survival with decreasing stage of disease (p = 0.017), with stage IA/IB/IIA patients achieving the lowest hazard ratio for death.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>56cecddff162a0.05346837</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage II RT after operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>45B1F5EE-16BC-48C3-93A5-E3761439B3CD</gtr:id><gtr:outcomeId>58b449cd30b244.68066831</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>AE33F8C7-EC1E-4963-AA62-AFA0710A11C8</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>56cf3d676c8348.74494909</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2015. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>6A226B43-2B15-47B6-960B-F8D1DD32349F</gtr:id><gtr:impact>&amp;quot;Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>56cef12a2bc777.16169506</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>9430564D-2EC4-4B42-B057-5884E17BC626</gtr:id><gtr:impact>&amp;quot;The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cf34dbe39ed7.88212088</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508, PMID: 10796873) BSG guideline 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>UK guidelines for the management of soft tissue sarcomas</gtr:guidelineTitle><gtr:id>F39FB37F-1C85-43BC-84E0-E14393EEF70B</gtr:id><gtr:outcomeId>58b54c84c594d7.13370120</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; 15939524) SOS/SUA guideline 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial urinary bladder cancer</gtr:guidelineTitle><gtr:id>17081BDE-FEFA-43CA-81AD-8EF1009AF5C8</gtr:id><gtr:outcomeId>58b42e42ecfff6.54773909</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage IV 1stLineCT inoperable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?</gtr:guidelineTitle><gtr:id>DBC74506-917A-4E04-A32C-87D5D296D215</gtr:id><gtr:impact>&amp;quot;Platinum-based chemotherapy improves survival in stage IV NSCLC compared with best supportive care. Note that this evidence is based on clinical trials conducted in fit patients, with predominant performance status 0-1, no unstable co-morbidities, adequate organ function and without uncontrolled brain metastases.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf32650e3164.84683471</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404; 15846628; 15603857) ASTRO guideline Def Adj RT 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline</gtr:guidelineTitle><gtr:id>5A4C0308-2DBE-42C5-81D1-3184DD30D288</gtr:id><gtr:impact>&amp;quot;Phase III studies and meta-analyses of PORT in completely resected (R0) LA NSCLC with N0-1 disease demonstrate inferior survival when compared to observation strategies; therefore, PORT therapy for this patient population is not routinely recommended.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628; PMID: 15603857)</gtr:impact><gtr:outcomeId>56cf39b18cc748.88739913</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>18493602-A858-4832-B95D-25960E6CCA2A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf0eb2964364.76478868</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>781AEF91-D5A9-4044-9EA4-551A0658933B</gtr:id><gtr:outcomeId>58b549613475a3.42284434</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>BDA79D72-1579-4835-8AA8-144EEC1FCDCF</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf33e6aafbd1.92351558</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 3.2016 Esophageal and Esophagogastric Junction Cancers</gtr:guidelineTitle><gtr:id>0755F547-63C9-44B6-B876-C9EF56F2D12B</gtr:id><gtr:outcomeId>58b54bcf5a44b5.19199138</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline</gtr:guidelineTitle><gtr:id>CEA8DAE0-74BE-4237-9FF9-21307AF31A8E</gtr:id><gtr:outcomeId>58b43309c7bc42.44963961</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) CCA guideline stage III PORT resected 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?</gtr:guidelineTitle><gtr:id>589DFC37-8DCF-46DF-9FC6-04FAE95A8CAA</gtr:id><gtr:outcomeId>58b548c433f101.10755336</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT resected 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC?</gtr:guidelineTitle><gtr:id>920CBF44-0AD6-44DF-BC45-8E1DB5212166</gtr:id><gtr:impact>&amp;quot;A meta-analysis demonstrates no clear evidence of an adverse or beneficial effect of PORT on survival in patients with pN2 disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>56cf3c765d4643.99221967</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III Adj CT operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>A12503E4-5792-4AB3-9E32-C1A5D9DEAD66</gtr:id><gtr:outcomeId>58b5488441ba89.78405384</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) CCO guideline post-op tx after operable 2016</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Postoperative adjuvant systemic therapy in completely resected non-small cell lung cancer. Guideline 7-1-2 Version 2</gtr:guidelineTitle><gtr:id>A835F535-9A79-47A8-9026-33F54006A84C</gtr:id><gtr:impact>&amp;quot;Key Evidence for recommendation 1&amp;quot;..... &amp;quot;An individual patient analysis of 26 randomized controlled trials (RCTs) demonstrated a significant survival benefit in patients receiving adjuvant chemotherapy compared with the observation group (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.81 to 0.92; p&amp;lt;0.0001) representing an absolute improvement of 4% (95% CI, 3 to 6) at five years.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>56d03efa9cc423.34084464</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2015 Bladder Cancer</gtr:guidelineTitle><gtr:id>7F44DE5C-8036-4C41-8FF1-04223C6C598A</gtr:id><gtr:impact>&amp;quot;Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy&amp;quot;....&amp;quot;A meta-analysis of 6 trials found a 25% mortality reduction with adjuvant chemotherapy, but the authors pointed out several limitations of the data and concluded that evidence is insufficient for treatment&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939530)</gtr:impact><gtr:outcomeId>56cdeade93d0c2.59141230</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT IPD (PMID: 24576776) CCA guideline stage III NeoAdj CT operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>7AA27BF2-EB16-48A2-8F20-C6F9FF55704A</gtr:id><gtr:outcomeId>58b54b437c7ab5.30552132</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>0A3D16BA-1128-4003-B810-27EA8379C74A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>56cf384c0a2ce0.28649446</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage III Adj CT operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>591ECFAD-530E-4713-8032-20F264693B51</gtr:id><gtr:outcomeId>58b4482830a8e6.09391018</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) CCMB guideline 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Evidence-based recommendations for the management of potentially curable esophageal carcinoma</gtr:guidelineTitle><gtr:id>125AEB11-3FC5-453D-BEB1-F8EBC80840E6</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9635705)</gtr:impact><gtr:outcomeId>56d03c4d81d674.12734527</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?</gtr:guidelineTitle><gtr:id>0361AF93-5E61-4C74-818A-DF2AE6661029</gtr:id><gtr:impact>&amp;quot;There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>56cf3ad7e83261.47681322</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2016 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>D6197123-2D62-4046-9540-78CDF700B883</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)</gtr:impact><gtr:outcomeId>56d042e165b678.57025376</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>6EABA23D-EF46-4B64-92AA-EEEDF8B9A4A0</gtr:id><gtr:impact>&amp;quot;Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease&amp;quot;
&amp;quot;When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>56cf415baedd39.10223987</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ESMO guideline stage M1 NSCLC 2016</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>209DD9D0-C6D4-4AB4-A387-6F32B270D62F</gtr:id><gtr:outcomeId>58b448e87c65f6.07702205</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID: 14602133) SEOM guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for cervical cancer 2015</gtr:guidelineTitle><gtr:id>D162897A-B40B-44EF-9BAC-0F0FD785AFA6</gtr:id><gtr:impact>&amp;quot;To date, neoadjuvant chemotherapy before either standard concurrent chemo-radiation or radical surgery is not a standard approach (Level of evidence IIa; Category of recommendation C).&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 14602133)</gtr:impact><gtr:outcomeId>56ced09f914ee6.26232803</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) SEOM guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervix CTRT IPD (PMID:19001332) SEOM guideline 2015</gtr:guidelineTitle><gtr:id>9A593EA1-B543-4035-8FED-BC109A293FBE</gtr:id><gtr:impact>&amp;quot;Primary cisplatin-based chemo-radiotherapy is the treatment of choice in locally advanced cervical cancer (Level of evidence Ia; Recommendation level A).&amp;quot; For stages IB2, IIA2, IIB-IVA), based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>56ced010938dd9.46491407</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404; 15846628) CCMB guideline 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Evidence-based recommendations for the management of non-small cell lung cancer (NSCLC)</gtr:guidelineTitle><gtr:id>268F8AA4-C235-4D18-B335-464E1692696F</gtr:id><gtr:impact>&amp;quot;Post-operative radiation therapy is not recommended as a standard of practice following complete resection of stage I and II NSCLC&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628)</gtr:impact><gtr:outcomeId>56cf3924238134.36897679</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) SEOM guideline 2015</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015</gtr:guidelineTitle><gtr:id>5DEB2E88-B381-4CCD-BA20-3829FAB08A07</gtr:id><gtr:impact>&amp;quot;PORT is not recommended for patients with completely resected stage I-II NSCLC (IA and IIA, respectively)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>56cf3cddd5cca4.53201255</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT before operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC?</gtr:guidelineTitle><gtr:id>30197CE9-578F-4C1C-A74D-C725DE5C7F7C</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>56cf3727047b30.15461019</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>57E8162D-C829-494C-8742-B03AE18507A0</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>56d040c761a445.07088550</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>2610C835-43AC-4621-A991-D5340132ACFD</gtr:id><gtr:outcomeId>58b447e79223d2.37105756</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>96597AC8-2D48-4537-9078-96567CBA8EBB</gtr:id><gtr:outcomeId>58b5464197e790.46536375</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2015</gtr:guidelineTitle><gtr:id>8C1944F9-69DF-4EF3-9400-DD695E487192</gtr:id><gtr:impact>In a meta-analysis of 11 trials involving 3,005 patients, platinum-based neoadjuvant chemotherapy was associated with improved 5-year overall and disease-free survival (5% and 9% absolute improvement, respectively), based on our systematic review and meta-analysis of IPD (PMID: 15939524)</gtr:impact><gtr:outcomeId>56cecc9b7a36c2.62633844</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT before operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC?</gtr:guidelineTitle><gtr:id>4C530CCC-3366-42E3-971F-07CF2195F050</gtr:id><gtr:outcomeId>58b44aa6d42d55.80040474</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2017 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>EC3C5A1A-52B9-4348-A62F-2240648EBDE5</gtr:id><gtr:outcomeId>58b54cd619fef2.42795064</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Colorectal Anti-EGFR SR (PMID:22118887) ASCO guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015</gtr:guidelineTitle><gtr:id>914EF1B2-CED3-4B59-B4F1-9E53DD519D32</gtr:id><gtr:outcomeId>58b434ec96a855.44015371</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>6EE4C133-040D-476D-B02A-5B1BD7173143</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>56d03fefb34352.50395333</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>06B4FA2C-00E6-4566-B412-FF5DD7DB9318</gtr:id><gtr:impact>&amp;quot;The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 24576776)</gtr:impact><gtr:outcomeId>56d04037e31cb4.51096267</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>5C6ECE50-5012-4BBE-90AF-B6C216AAE324</gtr:id><gtr:impact>&amp;quot;The standard of care for patients with inoperable stage II (node positive) and stage III is concurrent chemotherapy/RT&amp;quot;
&amp;quot;Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease.&amp;quot;
&amp;quot;When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>56d0410edd1570.93934611</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) NCCN guideline 2016</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2016 Cervical Cancer</gtr:guidelineTitle><gtr:id>414752B2-9438-4DDE-AF9D-ABA2835D377E</gtr:id><gtr:impact>&amp;quot;Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 20091632)</gtr:impact><gtr:outcomeId>56d03e2aa38cc4.35733482</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage III GoodPS inoperable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease?</gtr:guidelineTitle><gtr:id>E2B62C80-1C06-4EC6-9CE5-C3A2A22BABE5</gtr:id><gtr:outcomeId>58b448aa1b5a58.80800712</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage II RT after operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>7FD57943-BF8B-4F8D-B10D-418157614113</gtr:id><gtr:impact>&amp;quot;In patients who have had complete resection of stage II NSCLC, postoperative radiotherapy is not recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>56cf3baaf1ff11.69681828</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III Adj CT operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>975A96F2-CC5D-4F20-8377-EB8277C082A8</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)</gtr:impact><gtr:outcomeId>56cef3a9848060.70631449</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2017</gtr:guidelineTitle><gtr:id>93691D8E-DACB-4776-8BB8-C44A4D06611D</gtr:id><gtr:outcomeId>58b4313e5ac413.50068473</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ESMO guideline stage M1 NSCLC 2016</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>A71DE235-E416-42BA-AC9E-C53C2198763B</gtr:id><gtr:outcomeId>58b544a3b36a48.69977532</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>EE169270-7D1A-4FA7-B66F-F2D686A287EA</gtr:id><gtr:outcomeId>58b4479540bcb2.64503274</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17636828) CCA guideline stage III NeoAdj CT operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?</gtr:guidelineTitle><gtr:id>1199447E-C424-4486-92EC-1F4CD412D28E</gtr:id><gtr:outcomeId>58b44b2b005154.92792397</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:24576776) CCA guideline stage II CT before operable 2016</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>CE46B8A1-3393-4237-AF88-9361BA96CF5D</gtr:id><gtr:outcomeId>58b54b0e30f844.00873633</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>B2139057-FA68-4CF6-B1DF-49217053266A</gtr:id><gtr:outcomeId>58b54b891363f4.35688633</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) AHS guideline 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Endometrial cancer clinical practice guideline GYNE-002</gtr:guidelineTitle><gtr:id>C8C86C1A-1030-4571-9322-82D5442C02F8</gtr:id><gtr:impact>&amp;quot;..a meta-analysis by Humber, et al.in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response.&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>56cef07d4337d5.68388002</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.2.2015 Cervical Cancer</gtr:guidelineTitle><gtr:id>97DEE824-D525-44B1-BA3E-66FB58FE786E</gtr:id><gtr:impact>&amp;quot;A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; P &amp;lt;.001)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>56cece9b0e5f80.95635123</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ASTRO guideline Def Adj RT 2015</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline</gtr:guidelineTitle><gtr:id>84FDFE2B-9C54-4F11-BC83-15F37C13695D</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf0dbe811ee1.06613056</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2015</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>BF77CA8E-B9FF-4927-A7C2-75CBF221A2A5</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cf0e34dccc93.28026296</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of Aspirin Foundation Scientific Advisory Board</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>5B66F9A3-91CF-480A-9867-CEFB68F2252E</gtr:id><gtr:outcomeId>56db6a67eecac4.66440617</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.aspirin-foundation.com/scientific-advisory-board/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Until recently, the patch brand solely used in the PATCH trial was FemSeven. However, it is known that there are differences in the pharmacokinetic properties between different brands of patches. Therefore, a small sub-study embedded within the main trial is currently underway to evaluate an alternative brand of patches, namely the Progynova TS. This is to confirm the appropriate dose regimen for the Progynova for achieving castrate levels of testosterone within this setting. The primary outcome measure is castration rate at 12 weeks. Approximately 70 patients are to be randomised in allocation ratio 2:1 of patches:LHRHa. The sub-study is expected to be completed around end 2016.</gtr:description><gtr:id>E2FBD243-EE72-4DB4-BA2F-D92624F9A79D</gtr:id><gtr:impact>Results from the sub-study will be important for ensuring the long-term supply of the patches for the main PATCH trial, and broaden the re-purposing element of the study.</gtr:impact><gtr:outcomeId>56d57ba9b5ff13.83842041</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PATCH trial Progynova sub-study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer. Submitted as an amendment to the ICON8 protocol. First site opened to recruitment in July 2015. Recruitment on going as of February 2017 (expected to complete recruitment in July 2019). The trial is funded by CRUK and the MRC.</gtr:description><gtr:id>B5237586-D75B-497E-83C9-4942C3D6C645</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>58ac261f6cd917.93860825</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ICON8B</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.isrctn.com/ISRCTN10356387?q=&amp;filters=recruitmentCountry:Mexico&amp;sort=relevance&amp;offset=73&amp;totalResults=85&amp;page=1&amp;pageSize=100&amp;searchType=basic-search</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>PATCH is a randomised, non-inferiority, phase III trial comparing the clinical efficacy and side effect profile of transdermal oestrogen patches (OP) with Luteinising Hormone Releasing Hormone agonists (LHRHa) in the treatment of locally advanced and metastatic prostate cancer. 
Transcutaneous oestrogen avoids first-pass hepatic metabolism and therefore is not expected to be associated with the cardiovascular (CVS) toxicity previously seen with oral oestrogen. It may also avoid some of the serious side-effects associated with LHRHa.

The primary outcome measures will be overall survival and progression-free survival. The secondary outcome measures include prostate cancer specific survival, hormone levels, CVS and other toxicity, and quality of life. 

Data from the trial so far have shown promising evidence of the safety and efficacy of OP. Results from the first stage of the trial which aimed to assess the safety and activity of the patches have been published (n= 254), showing the patches produced castrate levels of testosterone similar to LHRHa, with no evidence of excess CVS toxicity. During the second stage, a pre-planned interim analysis (n=638) reviewed by the Independent Data Monitoring Committee in June 2013 led to the trial being extended for a phase III evaluation of the patch efficacy.</gtr:description><gtr:id>AD421C16-8FD6-4AF5-9A62-0D73C9C77977</gtr:id><gtr:impact>Results from a bone health sub-study embedded within PATCH have shown transdermal oestrogen protects against the bone mineral density loss seen with LHRHa. In addition, patients on patches appear to develop more favourable metabolic profiles and have a number of improved short-term quality of life outcomes compared to those on LHRHa therapy. However, the clinical efficacy of the patches needs confirming within a phase III trial setting before they can be considered as part of standard care in prostate cancer.</gtr:impact><gtr:outcomeId>56d5b84ce9e815.48011669</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PATCH trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The Add-Aspirin trial opened to recruitment in the UK in 2015 - it will investigate whether regular aspirin following treatment for an early stage common cancer can prevent recurrence and improve survival. Recruitment is currently ongoing. Funding for the trial is being provided by Cancer Research UK and the NIHR Heath Technology Assessment Programme.</gtr:description><gtr:id>F8E862D0-B027-43EE-BF27-0F7F2283A9ED</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>56db7475f3a746.03421445</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Add-Aspirin clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.addaspirintrial.org/</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Surveillance is an increasingly widely used management option for patients with stage I testicular seminoma, but requires regular radiological surveillance in order to detect recurrences early. CT scans are most widely used, but frequency varies considerably, and radiation associated with their use is a serious concern in this young, good prognosis population. The TRISST trial is factorial non-inferiority trial looking at 2 ways of potentially reducing radiation associated with surveillance scanning: a reduced scan frequency and/or replacement of CT scans with MRI scans. The trial is currently open to recruitment, due to complete in 2014, and is funded by CR UK</gtr:description><gtr:id>C2FD5BAA-A784-4DDF-807D-73149A14C4E8</gtr:id><gtr:impact>None as yet - this is the only randomised trial addressing these questions.</gtr:impact><gtr:outcomeId>cEprN7py7zo</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TRISST (TE24)</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Specimens from this completed clinical trial in 2nd line ovarian cancer, along with anonymised demographic and outcome data</gtr:description><gtr:id>45B2B008-9A9B-45A8-A98E-67BC2E9A45B2</gtr:id><gtr:impact>1st use of this collection not yet completed</gtr:impact><gtr:outcomeId>56dc4501e35dd7.58273403</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ICON6 tumour specimen collection &amp; associated clinical data</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Tumour and blood specimen collection from this ovarian cancer trial, along with anonymised corresponding demographic and clinical outcome data.</gtr:description><gtr:id>DAD6E358-4398-4091-BDA8-EA7176CA2540</gtr:id><gtr:impact>Multiple publications, listed as publication outputs</gtr:impact><gtr:outcomeId>56dc442d399546.56098418</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ICON7 trial specimen collection and corresponding clinical database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial.</gtr:description><gtr:id>F4A827C6-B8A8-4DDA-A508-23DD12785BF9</gtr:id><gtr:impact>No impact yet. The data will be made available to other researchers via an application process.</gtr:impact><gtr:outcomeId>56deae5a300685.77539051</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PATCH trial database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Cardiovascular (CVS) safety is as an important secondary endpoint within the PATCH trial. Detailed information on CVS outcomes are thus collected and regularly reviewed, which is challenging and time consuming, as it requires frequent exchanges of SAE forms and documentation between participating centres and the trial team. A pilot study will be undertaken to compare the CVS outcome data from the trial database with information from the National Institute for Cardiovascular Outcomes Research (NICOR) and the Hospital Episode Statistics (HES) databases for the patients already enrolled in PATCH, to validate methodology and data capture.</gtr:description><gtr:id>E79E9B95-22A8-4B0B-B494-15BD73BA1B26</gtr:id><gtr:impact>No impact yet as this work is currently in development.</gtr:impact><gtr:outcomeId>56dead12215bf9.05295209</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PATCH and NICOR/HES cardiovascular outcome data linkage</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial.</gtr:description><gtr:id>4A84A14A-00FF-46C7-913A-3988099DA4F3</gtr:id><gtr:impact>No impact yet. The data will be made available to other researchers via an application process.</gtr:impact><gtr:outcomeId>56ddaac1a81c67.83834894</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ICON8 Trial Database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>As requested by CTAAC, we have collected data to permit a cost effectiveness analysis in UK patients. The EORTC did not wish to include this in all patients but the expectation is that there will be sufficient UK patients to enable a reliable analysis to be carried out, and the methodology applied to the analysis will be made available to other national collaborating groups who may wish to carry out their own analysis on a country-specific basis.</gtr:description><gtr:id>1E2E31AD-7D23-43EE-A491-8ED81B1BF3C9</gtr:id><gtr:impact>None to date - analysese will be carried out at the end of the study.</gtr:impact><gtr:outcomeId>56d983162c1f60.41694383</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>BR14 - Health Economics Database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Clinical database for OE05 trial (neo-adjuvant chemotherapy for oesophageal adenocarcinoma).</gtr:description><gtr:id>3EB2FC4B-31E8-4DD5-BFAA-408CA9FEE235</gtr:id><gtr:impact>Not yet known.</gtr:impact><gtr:outcomeId>58bd50fc02f832.42906758</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Clinical database (OE05)</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial.</gtr:description><gtr:id>E5C8D06D-2196-40FD-8694-58000A337BDA</gtr:id><gtr:impact>Due to the size and scope of the planned trial (&amp;gt;10,000 participants with four different tumour types), the database is expected to provide a rich resource of information for use in future research beyond the original trial question. The data will be made available to other researchers via an application process.</gtr:impact><gtr:outcomeId>5458eb2d3cd371.58751066</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Add-Aspirin trial database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Clinical database for QUARTZ (Quality of life after treatment for brain metastases).</gtr:description><gtr:id>E4A44C30-8206-4C08-8261-AF7D518BE075</gtr:id><gtr:impact>Main trial paper published. Data available for internal and external use.</gtr:impact><gtr:outcomeId>58bd5094ea4394.03927675</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Clinical database (QUARTZ)</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A drug supply management system initially developed to coordinate the drug supply in the Add-Aspirin trial (double-blind, randomised, controlled trial) with the flexibility to be adapted for other trials.</gtr:description><gtr:id>13029B9C-246E-43AC-8BE1-0C593A0AC868</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b6da991f7e01.73818812</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Add-Aspirin trial drug supply management system</gtr:title><gtr:type>Data handling &amp; control</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial.</gtr:description><gtr:id>A7EB073B-98F6-47EA-8833-347C94047F7A</gtr:id><gtr:impact>No impact yet. The data will be made available to other researchers via an application process.</gtr:impact><gtr:outcomeId>56ddaa95c5eb30.18587596</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ICON8B Trial Database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Participants in the Add-Aspirin trial are being asked to provide blood and tumour samples at the time of registration in the trial. Samples are being collected at two central laboratories. The collection was initiated when the trial opened to recruitment (October 2015) and is currently ongoing. This will provide a unique and valuable resource for future translational research, and a broad programme of work utilising the samples is being planned, including investigation of the mechanisms of action responsible for anti-cancer effects of aspirin and identification of biomarkers for aspirin efficacy and toxicity in this setting.</gtr:description><gtr:id>F4C27B2C-583E-47C2-8999-BB7B029D1E6D</gtr:id><gtr:impact>No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process.</gtr:impact><gtr:outcomeId>56dc475657de29.68731498</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Add-Aspirin sample collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In PATCH, blood and urine samples were collected at various time points during trial follow-up for consenting patients randomised up to end October 2013. Baseline blood samples for future research are also being collected in all consenting patients. All samples are stored at Charing Cross Hospital Assay Laboratory.</gtr:description><gtr:id>61F3F1F1-CC4A-4E4B-B8BE-33BFCF947986</gtr:id><gtr:impact>These samples will be utilised in analyses to increase understanding of the underlying mechanisms for the potential benefits and adverse effects of the trial treatments, for example, for assessing changes in SHBG, oestrone/oestradiol ratio and bone biomarkers during time on treatment.</gtr:impact><gtr:outcomeId>56dde2d1b40506.75674215</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PATCH sample collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Collection of blood and tumour samples from OE05 trial.</gtr:description><gtr:id>4B8FC6D1-C4AA-405F-AF00-89607EC860AA</gtr:id><gtr:impact>Unknown</gtr:impact><gtr:outcomeId>58bd4fafe06373.52035575</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>OE05 sample collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TRISST trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee</gtr:description><gtr:id>4A284293-50BF-4C4C-A441-973A18C03377</gtr:id><gtr:impact>Trial is ongoing. The database is currently used for ongoing data collection, checking and monitoring.</gtr:impact><gtr:outcomeId>1BAA6CE3C99</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TRISST clinical trial database</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Participants in the ICON8B trial will be invited to consent to a translational research substudy to provide blood, plasma and tumour samples at the same time as consent to the main trial. Participants will be invited to consent at one of three levels depending on their preference and hospital site's resources. Sample coordination, storage and preliminary analysis is undertaken by Cambridge University. Dr James Brenton at Cambridge University has secured a CRUK grant for the funding of TRICON8B. Sample collection is planned to commence in q2 of 2016. Researchers will be able to access samples via a formal application process. This sample collection will represent a valuable resource for future translational work in ovarian cancer and will represent one of the largest bio-repositories for this disease area.</gtr:description><gtr:id>86A807E1-4306-4BCE-A892-710A396342EB</gtr:id><gtr:impact>No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process.</gtr:impact><gtr:outcomeId>56ddad44078980.65936646</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TRICON8B Sample Collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Repositry of tumour and blood samples from participants in the TE23 trial.</gtr:description><gtr:id>FCF116EC-CA0C-45CB-9366-C0AA6265923E</gtr:id><gtr:impact>Other research groups are able to gain access to the samples through application to the Trial Steering Committee. To date, samples have been shared with a research group at Cambridge University who will use the samples to investigate diagnostic and prognostic blood-based microRNA markers, and other short non-coding RNA profiles, in testicular germ cell tumours.</gtr:impact><gtr:outcomeId>XBnwWbZgLJH</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>TE23 sample collection</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Participants in the ICON8 trial were invited to consent to a translational research substudy to provide blood, plasma and tumour samples at the same time as consent to the main trial. Participants could consent at one of three levels depending on their preference and hospital site's resources. Sample coordination, storage and preliminary analysis is undertaken by Cambridge University. Researchers will be able to access samples via a formal application process. This sample collection will represent a valuable resource for future translational work in ovarian cancer and will represent one of the largest bio-repositories for this disease area.</gtr:description><gtr:id>66D3377B-A2BB-4A13-BBDB-575325B70531</gtr:id><gtr:impact>No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process.</gtr:impact><gtr:outcomeId>56ddac9aa45229.09497036</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TRICON8 Sample Collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>A drug supply management system tailored to the trial requirements has been developed in-house to provide a secure system for coordinating all aspects of the drug supply process in the study. The drug packaging and distribution team, as well as research staff and pharmacists at participating sites will have web-based access to the system, and it will allow close oversight of the whole process by the Trials Unit team. Input from all of the relevant parties has been sought in developing the system and it has been designed in such a way that it can subsequently be adapted for use in future trials conducted at the unit.</gtr:description><gtr:id>4E4A0D72-F776-45BF-8064-FCAD9713D4EF</gtr:id><gtr:impact>This in-house system may replace the need to out-source the management of drug supply processes, and so will have cost-saving implications both within Add-Aspirin and for future trials.</gtr:impact><gtr:outcomeId>5458efa5a34b27.69807580</gtr:outcomeId><gtr:title>Add-Aspirin Drug Supply Management System</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>45F94639-FBBA-433E-8CB8-E21842C85AD8</gtr:id><gtr:title>Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?</gtr:title><gtr:parentPublicationTitle>Current colorectal cancer reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39827175971d1d22521161df29129b90"><gtr:id>39827175971d1d22521161df29129b90</gtr:id><gtr:otherNames>Coyle C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1556-3790</gtr:issn><gtr:outcomeId>56cd9526210143.26470355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7D8CBCD-D958-4AD2-9D68-DB52744EBE4F</gtr:id><gtr:title>Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf985bd86ecf6b56c55c2469d65ff81e"><gtr:id>cf985bd86ecf6b56c55c2469d65ff81e</gtr:id><gtr:otherNames>Oza AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>56d6c86aa71261.40090264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FC2605E-CCF9-44C2-8616-26C0B03B6D14</gtr:id><gtr:title>Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbb3d1bce4efe3862425b8b3f06e17ad"><gtr:id>dbb3d1bce4efe3862425b8b3f06e17ad</gtr:id><gtr:otherNames>Kass-Iliyya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5a510386b0c860.84073848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1A7ECBE-C704-49D4-9A76-C1797405A192</gtr:id><gtr:title>Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc1cebf8d7bdc29258b3035f4f93eba7"><gtr:id>cc1cebf8d7bdc29258b3035f4f93eba7</gtr:id><gtr:otherNames>Andreassen CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58b69d8dd6d0a5.41306724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95B82A80-1E13-44CA-820C-66307339E0B1</gtr:id><gtr:title>Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d2ac172ff6bc9256060246dd201744c"><gtr:id>4d2ac172ff6bc9256060246dd201744c</gtr:id><gtr:otherNames>Lemanska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5a88499e99c908.49224002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC138C82-4925-4AC1-9057-BC13A1E1B3E4</gtr:id><gtr:title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b445939965a9.89259136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>666D252D-F389-48A8-960A-6B9E94315357</gtr:id><gtr:title>Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36a0787b7828d604408c3fe3a21119b8"><gtr:id>36a0787b7828d604408c3fe3a21119b8</gtr:id><gtr:otherNames>Gillessen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>59536a12abf076.46918661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A8B4846-1465-4E24-AFFE-384288F0CB82</gtr:id><gtr:title>A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56b9d002637520.74372769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00C5B1BD-EEBF-40B7-A3CB-7A024F8EA58B</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>56d5b1b4368026.53646208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC329941-2F54-428C-93E0-A0E38ECF6E3C</gtr:id><gtr:title>Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee6d6da88c36581a49a125d8c642532e"><gtr:id>ee6d6da88c36581a49a125d8c642532e</gtr:id><gtr:otherNames>Ledermann J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b990783c9803.44220746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E64633B6-0B8B-4429-B609-CD1ECA3A9F09</gtr:id><gtr:title>Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b4c65001c74ad81b6cb676b2531d2e8"><gtr:id>4b4c65001c74ad81b6cb676b2531d2e8</gtr:id><gtr:otherNames>Bielack SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d5737e200172.92101672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18D22A33-A72F-4253-96D4-983F7F75DED2</gtr:id><gtr:title>Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A&amp;nbsp;systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/143b5801e2cc50eb88a03a2653994aca"><gtr:id>143b5801e2cc50eb88a03a2653994aca</gtr:id><gtr:otherNames>Rydzewska LHM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>5a2fd5dacafca7.18898905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60DFE30C-2ABE-4CFE-A82F-E09B818ADB20</gtr:id><gtr:title>Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389dfa1738032a14b6cf77181edd3a4e"><gtr:id>389dfa1738032a14b6cf77181edd3a4e</gtr:id><gtr:otherNames>Gilbert DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>58a30c9fe585f2.89571881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55795937-CD38-496B-9323-F374E6614AD5</gtr:id><gtr:title>Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e76a8a0d73090fe4ee75ba8038539c8"><gtr:id>0e76a8a0d73090fe4ee75ba8038539c8</gtr:id><gtr:otherNames>Zhou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b98ec51b6ff0.34229672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6C4698F-F46F-492F-B819-7D4FB874C974</gtr:id><gtr:title>Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fea1c14569dbe43fb02c7858a951ed88"><gtr:id>fea1c14569dbe43fb02c7858a951ed88</gtr:id><gtr:otherNames>Cunningham D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa8e38a163800.18825252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7DC9DFD-DAE2-4937-939D-3058FDC6A7DB</gtr:id><gtr:title>Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eea847f35f9316d67f1b876ac8ba739"><gtr:id>5eea847f35f9316d67f1b876ac8ba739</gtr:id><gtr:otherNames>van den Bent MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5a9fee825588d6.55254454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88D3ED81-7799-4391-AD83-3BE194C482B4</gtr:id><gtr:title>Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a31d615aa3770.82575710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A3D02A-8E0E-4177-936B-AC625CED7496</gtr:id><gtr:title>Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d53b218500ae8d4b2ed732abfeb2ee1"><gtr:id>7d53b218500ae8d4b2ed732abfeb2ee1</gtr:id><gtr:otherNames>Faria R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5a9a999e524e11.79609928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E322161-CC2E-43E1-AFE5-EE9075CA61E8</gtr:id><gtr:title>Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3691df88f4864737415fd0fa1d54571b"><gtr:id>3691df88f4864737415fd0fa1d54571b</gtr:id><gtr:otherNames>Reijneveld J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58ca6cefe81ed5.20459748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DA21FDE-D649-46C1-B1DF-E8AED4549192</gtr:id><gtr:title>Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6587956def9e82143990da67c900b68b"><gtr:id>6587956def9e82143990da67c900b68b</gtr:id><gtr:otherNames>Hale MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58bd387d82f377.76444626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5C93345-D049-40A2-A2B9-349375790864</gtr:id><gtr:title>Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af0707d338e2c1c3c05688ae01f64aed"><gtr:id>af0707d338e2c1c3c05688ae01f64aed</gtr:id><gtr:otherNames>Ahmed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b69d8d9b0137.33010439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C3490C4-5E65-47B0-819D-5A9D4882E291</gtr:id><gtr:title>Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93f2b024776696f8d8ff632f0afb4feb"><gtr:id>93f2b024776696f8d8ff632f0afb4feb</gtr:id><gtr:otherNames>Baumert B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58ca6c861120b9.47664932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8C183BE-E18F-42F2-8FC9-2F4C6B2C81F8</gtr:id><gtr:title>Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81e8bd0d98fbc0e65dba6da22bbc3265"><gtr:id>81e8bd0d98fbc0e65dba6da22bbc3265</gtr:id><gtr:otherNames>Frouws MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58c00aee037376.05106163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9193E561-11AE-470D-84CA-C34C5DED77AC</gtr:id><gtr:title>A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5968c417ce2338.53044955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FDDA01A-1A76-4B0E-A007-EFF3C9DB2EE0</gtr:id><gtr:title>The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update.</gtr:title><gtr:parentPublicationTitle>European urology focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2405-4569</gtr:issn><gtr:outcomeId>56d5aef2f3b0d8.46566452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4956AD0D-AD04-44B0-9CD3-1DAB55C7C066</gtr:id><gtr:title>Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c7a6dfeba2be65bf04324bc978d3af6"><gtr:id>2c7a6dfeba2be65bf04324bc978d3af6</gtr:id><gtr:otherNames>Davarzani N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>5aa58bc84157d4.53114768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1B9C178-0347-47EC-86B5-784BFAC5F3A3</gtr:id><gtr:title>Polypill is not just for cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b90bb5f5279d04ac08ba26708c2f0ca7"><gtr:id>b90bb5f5279d04ac08ba26708c2f0ca7</gtr:id><gtr:otherNames>Cafferty FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a97ad86025f56.75923478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54836393-594F-4A34-8D3A-FA9FF194B3C8</gtr:id><gtr:title>Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc9258bfbae02494f9f086975246e252"><gtr:id>bc9258bfbae02494f9f086975246e252</gtr:id><gtr:otherNames>Smyth E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa8e47202c860.39838226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17E4D293-818B-48B5-8098-4EB943D06F4A</gtr:id><gtr:title>Salvage Treatment After Radical Prostatectomy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>59878538eaa5b3.30955917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88E6F607-8185-4A36-B871-364C90D3BF49</gtr:id><gtr:title>Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7744e8e09b3d0fd0cf776341fadf5194"><gtr:id>7744e8e09b3d0fd0cf776341fadf5194</gtr:id><gtr:otherNames>South A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2405-4569</gtr:issn><gtr:outcomeId>56d5737fc97886.40936996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A64E45B-837D-4909-87E1-CD54E358C092</gtr:id><gtr:title>EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8a9b8e08753a466b4874512f5edd1ce"><gtr:id>f8a9b8e08753a466b4874512f5edd1ce</gtr:id><gtr:otherNames>Whelan JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>56d5738106daf6.44062193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F36C478-F883-411E-97A8-C224493CBEF8</gtr:id><gtr:title>Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89617b9d24b04255c06955063acd4a7c"><gtr:id>89617b9d24b04255c06955063acd4a7c</gtr:id><gtr:otherNames>Mason MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d5737f99c8f6.82782342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45AB55E3-5B6D-439D-9AE0-75D5CDD82A08</gtr:id><gtr:title>Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1437662d2ddeda92da753b4b2a41f3c"><gtr:id>d1437662d2ddeda92da753b4b2a41f3c</gtr:id><gtr:otherNames>Farmer RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58b98c81d7e573.29152218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99FB6233-651F-4251-B352-EB3C44B4CE78</gtr:id><gtr:title>Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec8b93205837d4d7ae455846e0a71637"><gtr:id>ec8b93205837d4d7ae455846e0a71637</gtr:id><gtr:otherNames>Eichenauer DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>59bf9845c48794.28754179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>397E7A7F-7152-4C8D-B525-4CD65B0BBD25</gtr:id><gtr:title>Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b836cb249f51.31621681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAB7F33A-A87D-40D8-8468-58A2522AB23A</gtr:id><gtr:title>Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389dfa1738032a14b6cf77181edd3a4e"><gtr:id>389dfa1738032a14b6cf77181edd3a4e</gtr:id><gtr:otherNames>Gilbert DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5a8c2457daff38.20673204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA83D669-2B1C-497E-A53F-84BCB8E6A936</gtr:id><gtr:title>Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc9258bfbae02494f9f086975246e252"><gtr:id>bc9258bfbae02494f9f086975246e252</gtr:id><gtr:otherNames>Smyth E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5aa58bc76f0712.68275129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A71BB524-255D-4135-8D66-D26A6878810A</gtr:id><gtr:title>Repurposing Vitamin D as an Anticancer Drug.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389dfa1738032a14b6cf77181edd3a4e"><gtr:id>389dfa1738032a14b6cf77181edd3a4e</gtr:id><gtr:otherNames>Gilbert DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>56d5d2df82a941.22105502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8DDC9CB-FAB8-4670-A6D2-73D22D3B1634</gtr:id><gtr:title>Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.</gtr:title><gtr:parentPublicationTitle>The Journal of molecular diagnostics : JMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19c26a474e2dea6fb8bf670765ea183b"><gtr:id>19c26a474e2dea6fb8bf670765ea183b</gtr:id><gtr:otherNames>Zhang S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-1578</gtr:issn><gtr:outcomeId>56d80f2a732665.25068000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>880DB768-F41F-49BE-9A11-CE2BFBD9D708</gtr:id><gtr:title>Whole brain radiotherapy for non-small cell lung cancer - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f3bcbf8d92b994aab1ff85bee885c3c"><gtr:id>7f3bcbf8d92b994aab1ff85bee885c3c</gtr:id><gtr:otherNames>Langley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa58bc794ca83.69833887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6765BDF-E295-4A51-961E-CF32CB90BFA2</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58b98f57a1f775.39638054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F58A525-15EE-44AF-ABB8-D17E553420F5</gtr:id><gtr:title>Postoperative radiotherapy for non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4225def80303de4a226d3422d01ee2"><gtr:id>7c4225def80303de4a226d3422d01ee2</gtr:id><gtr:otherNames>Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>58b41c0a500fc4.41367570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A8AD3E8-AFD8-4AAA-A5F9-09A8D0E198A4</gtr:id><gtr:title>Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56e022f0837cf2.77812299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0AE867F-FF40-415A-83AD-670970D56282</gtr:id><gtr:title>Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb1c6d0ec3479d895439deb81214a878"><gtr:id>fb1c6d0ec3479d895439deb81214a878</gtr:id><gtr:otherNames>Alderson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa58bc8219938.65167785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>344D60E6-6919-4E3E-B68D-67D09FA4C85E</gtr:id><gtr:title>Co-enrolment of Participants into Multiple Cancer Trials: Benefits and Challenges.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b90bb5f5279d04ac08ba26708c2f0ca7"><gtr:id>b90bb5f5279d04ac08ba26708c2f0ca7</gtr:id><gtr:otherNames>Cafferty FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5a97adaf7d5a75.13286119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB6A667B-8DFF-4E43-9AF5-09E0461914C8</gtr:id><gtr:title>Aspirin in the 21st century-common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK.</gtr:title><gtr:parentPublicationTitle>Ecancermedicalscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76f55bf11bf9112330ef9840251dd7d0"><gtr:id>76f55bf11bf9112330ef9840251dd7d0</gtr:id><gtr:otherNames>Smith T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1754-6605</gtr:issn><gtr:outcomeId>56d811c99e5891.26208038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FE99C67-5761-4C8A-8153-08B604653131</gtr:id><gtr:title>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83a8cb1cf41b81e09579a58782c77faf"><gtr:id>83a8cb1cf41b81e09579a58782c77faf</gtr:id><gtr:otherNames>Marina NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>58b696ffeba107.16826546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B946FF07-C25B-4018-ACCA-3EF58A486C55</gtr:id><gtr:title>Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9098f85cfb4aaf62ae766b74b6b220c2"><gtr:id>9098f85cfb4aaf62ae766b74b6b220c2</gtr:id><gtr:otherNames>Kehoe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d803962f10e6.10855048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C4343CC-7245-4848-AA09-12F7D3C6D884</gtr:id><gtr:title>Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.</gtr:title><gtr:parentPublicationTitle>JAMA oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78701698503dc7c36df7feddb140480b"><gtr:id>78701698503dc7c36df7feddb140480b</gtr:id><gtr:otherNames>Smyth EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2374-2437</gtr:issn><gtr:outcomeId>58bd387d2d26d4.00067495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE5D1CAC-D1CD-4524-A6CB-034AC3FC4062</gtr:id><gtr:title>Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39827175971d1d22521161df29129b90"><gtr:id>39827175971d1d22521161df29129b90</gtr:id><gtr:otherNames>Coyle C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>58a31123d3e361.04967000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E08B9A3-F561-411C-8992-2AC0ACB000D7</gtr:id><gtr:title>Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/593393822da26709697a3e72eafc6de5"><gtr:id>593393822da26709697a3e72eafc6de5</gtr:id><gtr:otherNames>Stark DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>5a9aa639c99e09.74193633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18011444-534B-40FA-AA74-0DC26E00B86E</gtr:id><gtr:title>Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397).</gtr:title><gtr:parentPublicationTitle>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d2ac172ff6bc9256060246dd201744c"><gtr:id>4d2ac172ff6bc9256060246dd201744c</gtr:id><gtr:otherNames>Lemanska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-9343</gtr:issn><gtr:outcomeId>58dd0da8d613f8.46660300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D0A4CC-E58F-4DE8-8C10-3358E6FE43F4</gtr:id><gtr:title>High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/968bb38ba508b0d86999082d4c518998"><gtr:id>968bb38ba508b0d86999082d4c518998</gtr:id><gtr:otherNames>Downing A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5a9aa99ec36d57.25014037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAC8939E-F559-467D-8032-2A7C94D02A9E</gtr:id><gtr:title>Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcae6cfc9bc5f7490d8317b14949c11f"><gtr:id>fcae6cfc9bc5f7490d8317b14949c11f</gtr:id><gtr:otherNames>Olson TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56e022f0c9f2e6.56041299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEDE2D03-197E-4B08-AD39-18C938D7A89F</gtr:id><gtr:title>Neoadjuvant chemotherapy in oesophageal adenocarcinoma - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb1c6d0ec3479d895439deb81214a878"><gtr:id>fb1c6d0ec3479d895439deb81214a878</gtr:id><gtr:otherNames>Alderson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa58bc8027684.18895693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1246CAC1-20E5-4E2A-B12C-076BC62C8501</gtr:id><gtr:title>Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc375f14ceef8e17abe7868570792812"><gtr:id>dc375f14ceef8e17abe7868570792812</gtr:id><gtr:otherNames>Sylvester RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e022f0534992.29046118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C105B569-F3A8-4D6D-AE12-E0551100A5C6</gtr:id><gtr:title>A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b7166c6c54508fe2e690fa7ef769e3b"><gtr:id>4b7166c6c54508fe2e690fa7ef769e3b</gtr:id><gtr:otherNames>Huddart RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e01166245ac2.44953259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CF964F6-AA76-406F-84BB-1DAFEA764AD2</gtr:id><gtr:title>Primary chemotherapy versus primary surgery for ovarian cancer - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9098f85cfb4aaf62ae766b74b6b220c2"><gtr:id>9098f85cfb4aaf62ae766b74b6b220c2</gtr:id><gtr:otherNames>Kehoe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d803965b6899.10186268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>891355B7-6C1C-4F81-82FB-19F54B12BED4</gtr:id><gtr:title>Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491610a8bee653098da773881acc19ad"><gtr:id>491610a8bee653098da773881acc19ad</gtr:id><gtr:otherNames>Mulvenna P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5891ae9c541831.31570712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABFC8697-EFF4-4048-B02B-FCFF1082BE20</gtr:id><gtr:title>Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a2b4a60143f694fb37017f02d8dd28a"><gtr:id>9a2b4a60143f694fb37017f02d8dd28a</gtr:id><gtr:otherNames>Kerns SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>596bcfcb3b2241.29523464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88CB9706-93A2-48F0-BB0D-2CD6B24EABAB</gtr:id><gtr:title>ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39827175971d1d22521161df29129b90"><gtr:id>39827175971d1d22521161df29129b90</gtr:id><gtr:otherNames>Coyle C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>58a30fe5760215.31766716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBB12CDD-DCBE-43C3-BFC4-DFC6A3767090</gtr:id><gtr:title>Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78701698503dc7c36df7feddb140480b"><gtr:id>78701698503dc7c36df7feddb140480b</gtr:id><gtr:otherNames>Smyth EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>58b3ea670811c6.59444189</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/28</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>